U.S. patent application number 10/429681 was filed with the patent office on 2004-01-01 for nav2 channel gene-deficient non-human animals.
Invention is credited to Noda, Masaharu, Watanabe, Eiji.
Application Number | 20040003425 10/429681 |
Document ID | / |
Family ID | 27344267 |
Filed Date | 2004-01-01 |
United States Patent
Application |
20040003425 |
Kind Code |
A1 |
Noda, Masaharu ; et
al. |
January 1, 2004 |
Nav2 channel gene-deficient non-human animals
Abstract
An object of the present invention is to provide a null mutant
non-human animal showing salt intake behavior similar to that of
wild-type animals under water-sufficient conditions and showing
much more intakes of hypertonic saline compared with wild-type
animals under water- and salt-depleted conditions, for example, an
Na.sub.v2 gene-deficient non-human animal, which is useful as a
model animal of excessive salt intake experiments. The object will
be attained by following process: mouse genomic libraries are
screened with rat NaG cDNA as a probe, then Na.sub.v2 gene of
genomic DNA is isolated, and a targeting vector is constructed by
inserting marker gene such as neo gene into the exon of Na.sub.v2.
After thus constructed targeting vector is induced to ES cells,
homologously recombined ES cells are selected, then germ line
chimeric mice are constructed with this ES cells strain, and they
are hybridized with the wild-type mice and heterozygous mutant mice
are obtained. By intercrossing of thus obtained heterozygous mutant
mice, Na.sub.v2 knockout mice are constructed.
Inventors: |
Noda, Masaharu;
(Okazaki-shi, JP) ; Watanabe, Eiji; (Okazaki-shi,
JP) |
Correspondence
Address: |
VENABLE, BAETJER, HOWARD AND CIVILETTI, LLP
P.O. BOX 34385
WASHINGTON
DC
20043-9998
US
|
Family ID: |
27344267 |
Appl. No.: |
10/429681 |
Filed: |
May 6, 2003 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10429681 |
May 6, 2003 |
|
|
|
09920653 |
Aug 3, 2001 |
|
|
|
Current U.S.
Class: |
800/18 ;
435/320.1; 435/354; 435/6.16; 435/69.1; 530/350; 536/23.2 |
Current CPC
Class: |
A61P 3/12 20180101; C07K
14/705 20130101; A01K 2227/105 20130101; A01K 2217/072 20130101;
A01K 2217/00 20130101; C12N 15/8509 20130101; A61P 25/00 20180101;
A01K 2217/05 20130101; A01K 67/0276 20130101; A61K 38/00 20130101;
A01K 2217/075 20130101; A01K 2207/15 20130101; C07K 2319/00
20130101; A01K 2267/03 20130101 |
Class at
Publication: |
800/18 ; 530/350;
536/23.2; 435/69.1; 435/6; 435/320.1; 435/354 |
International
Class: |
A01K 067/027; C12Q
001/68; C07H 021/04; C12N 005/06; C07K 014/705 |
Foreign Application Data
Date |
Code |
Application Number |
Aug 4, 2000 |
JP |
2000-237320 |
Aug 9, 2000 |
JP |
2000-241637 |
Jul 23, 2001 |
JP |
2001-222263 |
Claims
What is claimed is
1. A null mutant non-human animal characterized in showing salt
intake behavior similar to that of wild-type animals under
water-sufficient conditions and showing much more intakes of
hypertonic saline compared with wild-type animals under water- and
salt-depleted conditions.
2. The null mutant non-human animal according to claim 1, wherein
the function of Na.sub.v2 gene is deficient on its chromosome.
3. The null mutant non-human animal according to claim 2, wherein
the non-human animal is a rodent.
4. The null mutant non-human animal according to claim 3, wherein
the rodent is a mouse.
5. A gene that codes for a protein acting as a sensor of
extracellular sodium ion level.
6. The gene according to claim 5, wherein the protein is comprised
of amino acid sequence shown in Seq. ID No. 3, or is comprised of
amino acid sequence where one or a few amino acids are deficient,
substituted, or added, in amino acid sequence shown in Seq. ID No.
3.
7. The gene according to claim 5, which is comprised of DNA that
contains a base sequence shown in Seq. ID No. 2 or its
complimentary sequence, and a part or whole of those sequences.
8. The gene according to claim 5, which is comprised of DNA being
hybridized under stringent conditions with DNA that contains a base
sequence shown in Seq. ID No. 2 or its complimentary sequence, and
a part of or whole of those sequences.
9. A protein acting as a sensor of extracellular sodium ion
level.
10. The protein according to claim 9, which is comprised of amino
acid sequence shown in Seq. ID No. 3.
11. The protein according to claim 9, which is comprised of amino
acid sequence where one or a few amino acids are deficient,
substituted, or added, in amino acid sequence shown in Seq. ID No.
3.
12. A fusion protein created by combining a protein acting as a
sensor of extracellular sodium ion level and a marker protein
and/or a peptide tag.
13. The fusion protein according to claim 12, wherein the protein
acting as a sensor of extracellular sodium ion level is the protein
according to claims 10 or 11.
14. An antibody which specifically combines with a protein acting
as a sensor of extracellular sodium ion level.
15. The antibody according to claim 14, wherein the protein acting
as a sensor of extracellular sodium ion level is the protein
according to claims 10 or 11.
16. The antibody according to claims 14 or 15, wherein the antibody
is a monoclonal antibody.
17. A host cell which contains an expression system that can
express a protein acting as a sensor of extracellular sodium ion
level.
18. The host cell according to claim 17, wherein the protein acting
as a sensor of extracellular sodium ion level is the protein
according to claims 10 or 11.
19. A transgenic non-human animal which excessively expresses a
protein acting as a sensor of extracellular sodium ion level.
20. The transgenic non-human animal according to claim 19, wherein
the protein acting as a sensor of extracellular sodium ion level is
the protein according to claims 10 or 11.
21. The transgenic non-human animal according to claims 19 or 20,
wherein the non-human animal is a mouse or a rat.
22. A method of screening a material that promotes or suppresses
the function or the expression of a protein acting as a sensor of
extracellular sodium ion level characterized in using a cell that
expresses a protein acting as a sensor of extracellular sodium ion
level, and a subject material.
23. The method of screening a material that promotes or suppresses
the function or the expression of a protein acting as a sensor of
extracellular sodium ion level according to claim 22, wherein the
cell that expresses a protein acting as a sensor of extracellular
sodium ion level is the host cell according to claims 17 or 18.
24. A method of screening a material that promotes or suppresses
the function or the expression of a protein acting as a sensor of
extracellular sodium ion level characterized in using the non-human
animal according to any one of claims 1 to 4 or the non-human
animal according to any one of claims 19 to 21, and a subject
material.
25. A material that promotes or suppresses the function or the
expression of a protein acting as a sensor of extracellular sodium
ion level characterized in being available through the screening
method according to any one of claims 22 to 24.
26. A medical compound used for curing patients who need promotion
of the function or enhancement of the expression of a protein
acting as a sensor of extracellular sodium ion level, and
containing the protein according to any one of claims 9 to 11 or
the material that promotes the function or the expression of a
protein acting as a sensor of extracellular sodium ion level
according to claim 25 as its effective components.
27. A medical compound used for curing patients who need
suppression of the function or the expression of a protein acting
as a sensor of extracellular sodium ion level, and containing the
protein according to any one of claims 9 to 11 or the material that
suppresses the function or the expression of a protein acting as a
sensor of extracellular sodium ion level according to claim 25 as
its effective components.
Description
TECHNICAL FIELD TO WHICH THE INVENTION PERTAINS
[0001] This invention relates to a non-human animal whose function
of Na.sub.v2 channel gene is deficient on its chromosome that shows
salt intake behavior similar to that of wild-type animals under
water-sufficient conditions and shows much more intakes of
hypertonic saline compared with wild-type animals under water- and
salt-depleted conditions, a protein acting as a sensor of
extracellular soon ion level, a gene that codes for said protein,
and the like.
PRIOR ART
[0002] Voltage-dependent sodium channels as well as
voltage-dependent potassium channels are known as the ion channels
which play the main role in the generation and the propagation of
action potential in excitable cells such as nerve cells, muscle
cells, and the like. A sodium channel molecule comprises an
ion-selective channel with voltage-sensors, and is consisted of
.alpha.-subunits comprised of glycoprotein of 270 kDa, and 1 or 2
smaller .beta.-subunits. Voltage-dependent sodium channels are
closed when the cell membrane is in resting potential (normally -70
to -90 mV), but they open when the cell membrane depolarizes and
close approximately 1 msec later. Therefore, it is said that a
sodium channel protein molecule has a voltage-sensor that senses
the membrane potential, and opens the channel, a selective filter
for filtering a sodium ion selectively, and inactivation gate.
[0003] Since the identification of a sodium channel protein
.alpha.-subunit cDNA type I, II, and III in the brain (Nature 320,
188-192(1986), FEBS Lett. 228, 187-194(1988)) by the inventors of
the present invention, multiple structurally related isoforms of
the .alpha.-subunit have been cloned from various tissues, forming
a multigene family. In addition to the excitable cells, it has
recently been found that glial cells also express voltage-sensitive
sodium currents (Trends Neurosci. 19, 325-332(1996)). In situ
hybridization, RT-PCR, Northern blot analysis and
immunocytochemistry have clearly demonstrated the presence of
brain-type I, II, III, H1, Na.sub.s, NaCH6 and the like in glial
cells (Glia 26, 92-96(1999)). However, the functional roles of
these voltage-dependent sodium channels in so-called electrically
inexcitable cells have not yet been delineated.
[0004] Several years ago, a partial cDNA homologous to the
voltage-dependent sodium channel .alpha.-subunit was cloned from a
cDNA library derived from rat astrocytes, and designated NaG (Proc.
Natl. Acad. Sci. USA 89, 7272-7276(1992)). Subsequently, similar
.alpha.-subunit isoforms were independently cloned from various
animal species: Na.sub.v2.1 from human heart (Proc. Natl. Acad.
Sci. USA 89, 4893-4897(1992)), Na.sub.v2.3 from a mouse arterial
tumor cell line (J. Biol. Chem. 269, 30125-30131), and SCL11 from
rat dorsal root ganglia which corresponds to splicing variant of
NaG (FEBS Lett. 400, 183-187(1997)). From the sequence homology, it
is possible to assume that they are species orthologues and to
classify them into another subfamily of .alpha.-subunit of
voltage-dependent sodium channels (NaCh), namely, subfamily 2 NaCh
(Na.sub.v2). Their overall amino acid sequences had less than 50%
identity with those of the previously cloned voltage-dependent
sodium channels, and the sequences are characterized as rather
unique even in the regions associated with ion selectivity and
voltage-dependent activation and inactivation. Such regions are
perfectly conserved in all other subfamily members, suggesting that
the Na.sub.v2 has specific channel properties. However, all the
attempts to express functional Na.sub.v2 channels in heterologous
expression systems using such as Xenopus oocytes, CHO cells, HEK293
cells and the like have been unsuccessful, and the function of
Na.sub.v2 channels in vivo has been totally unknown.
[0005] NaG/SCL11 was originally thought to be one of the
voltage-dependent sodium channels (NaChs) expressed in astrocytes
because it was cloned from astrocytes, but subsequent in situ
hybridization studies revealed that Na.sub.v2 is expressed not in
astrocytes but in Schwann cells and the spinal sensory neurons in
vivo (Glia 21, 269-276(1997)). Relatively high levels of NaG mRNA
are detected outside of the nervous system, particularly in lung
and heart. In addition, RNase protection and Northern blot analyses
demonstrated the presence of NaG mRNA in the central nervous
system. However, it has been reported that NaG mRNA was not
detectable by in situ hybridization using a non-isotopic probe
except in the mesencephalic nucleus V. (Mol. Brain Res. 45,
71-82(1997)), suggesting that NaG mRNA is broadly expressed at a
low level throughout the central nervous system or expressed
restrictedly in specific regions in the central nervous system. The
distribution, of the NaG channel among these diverse tissues and
cell-types including electrically inexcitable cells, suggests a
role for this channel other than in action-potential generation and
propagation.
AN OBJECT TO BE ATTAINED BY THE INVENTION
[0006] So far, a model animal for excessive salt intake experiments
showing salt intake behavior similar to that of wild-types under
water-sufficient conditions and showing abnormal intakes of
hypertonic saline compared with wild-types under water- and
salt-depleted conditions has not been known. A protein acting as a
sensor of extracellular sodium ion level, and a gene that codes for
such protein have not been known as well. The object of the present
invention is to provide a null mutant non-human animal showing salt
intake behavior similar to that of wild-type animals under
water-sufficient conditions and showing much more intakes of
hypertonic saline compared with wild-type animals under water- and
salt-depleted conditions, for example, an Na.sub.v2 gene deficient
non-human animal, which is useful as said model animal of excessive
salt intake experiments, a protein acting as a sensor of
extracellular sodium ion level, and a gene that codes for said
protein.
MEANS TO ATTAIN THE OBJECT
[0007] The inventors have been intensely studied the function and
the role of Na.sub.v2 channel in vivo, which was unknown, and
generated Na.sub.v2 channel knockout mice, then confirmed that
Na.sub.v2 channel plays a role to sense and control sodium ion
level in body fluids. Subsequently, it has been found that these
Na.sub.v2 channel knockout mice show salt intake behavior similar
to that of wild-types under water-sufficient conditions and show
abnormal behavior such as much more intakes of hypertonic saline
compared with wild-types under water- and salt-depleted conditions,
and thus the present invention has been completed.
[0008] In other words, this invention relates to a null mutant
non-human animal characterized in showing salt intake behavior
similar to that of wild-type animals under water-sufficient
conditions and showing much more intakes of hypertonic saline
compared with wild-type animals under water- and salt-depleted
conditions (claim 1), the null mutant non-human animal according to
claim 1, wherein the function of Na.sub.v2 gene is deficient on its
chromosome (claim 2), the null mutant non-human animal according to
claim 2, wherein the non-human animal is a rodent (claim 3), and
the null mutant non-human animal according to claim 3, wherein the
rodent is a mouse (claim 4).
[0009] This invention also relates to a gene that codes for a
protein acting as a sensor of extracellular sodium ion level (claim
5), the gene according to claim 5, wherein the protein is comprised
of amino acid sequence shown in Seq. ID No. 3, or is comprised of
amino acid sequence where one or a few amino acids are deficient,
substituted, or added, in amino acid sequence shown in Seq. ID No.
3 (claim 6), the gene according to claim 5, which is comprised of
DNA that contains a base sequence shown in Seq. ID No. 2 or its
complimentary sequence, and a part or whole of those sequences
(claim 7), and the gene according to claim 5, which is comprised of
DNA being hybridized under stringent conditions with DNA that
contains a base sequence shown in Seq. ID No. 2 or its
complimentary sequence, and a part of or whole of those sequences
(claim 8).
[0010] This invention relates to a protein acting as a sensor of
extracellular sodium ion level (claim 9), the protein according to
claim 9, which is comprised of amino acid sequence shown in Seq. ID
No. 3 (claim 10), the protein according to claim 9, which is
comprised of amino acid sequence where one or a few amino acids are
deficient, substituted, or added, in amino acid sequence shown in
Seq. ID No. 3 (claim 11), a fusion protein created by combining a
protein acting as a sensor of extracellular sodium ion level and a
marker protein and/or a peptide tag (claim 12), and the fusion
protein according to claim 12, wherein the protein acting as a
sensor of extracellular sodium ion level is the protein according
to claims 10 or 11 (claim 13).
[0011] This invention also relates to an antibody which
specifically combines with a protein acting as a sensor of
extracellular sodium ion level (claim 14), the antibody according
to claim 14, wherein the protein acting as a sensor of
extracellular sodium ion level is the protein according to claims
10 or 11 (claim 15), and the antibody according to claims 14 or 15,
wherein the antibody is a monoclonal antibody (claim 16).
[0012] This invention relates to a host cell which contains an
expression system that can express a protein acting as a sensor of
extracellular sodium ion level (claim 17), and the host cell
according to claim 17, wherein the protein acting as a sensor of
extracellular sodium ion level is the protein according to claims
10 or 11 (claim 18).
[0013] This invention also relates to a transgenic non-human animal
which excessively expresses a protein acting as a sensor of
extracellular sodium ion level (claim 19), the transgenic non-human
animal according to claim 19, wherein the protein acting as a
sensor of extracellular sodium ion level is the protein according
to claims 10 or 11 (claim 20), and the transgenic non-human animal
according to claims 19 or 20, wherein the non-human animal is a
mouse or a rat (claim 21).
[0014] This invention relates to a method of screening a material
that promotes or suppresses the function or the expression of a
protein acting as a sensor of extracellular sodium ion level
characterized in using a cell that expresses a protein acting as a
sensor of extracellular sodium ion level, and a subject material
(claim 22), the method of screening a material that promotes or
suppresses the function or the expression of a protein acting as a
sensor of extracellular sodium ion level according to claim 22,
wherein the cell that expresses a protein acting as a sensor of
extracellular sodium ion level is the host cell according to claims
17 or 18 (claim 23), and a method of screening a material that
promotes or suppresses the function or the expression of a protein
acting as a sensor of extracellular sodium ion level characterized
in using the non-human animal according to any one of claims 1 to 4
or the non-human animal according to any one of claims 19 to 21,
and a subject material (claim 24).
[0015] This invention relates to a material that promotes or
suppresses the function or the expression of a protein acting as a
sensor of extracellular sodium ion level characterized in being
available through the screening method according to any one of
claims 22 to 24 (claim 25), a medical compound used for curing
patients who need promotion of the function or enhancement of the
expression of a protein acting as a sensor of extracellular sodium
ion level, and containing the protein according to any one of
claims 9 to 11 or the material that promotes the function or the
expression of a protein acting as a sensor of extracellular sodium
ion level according to claim 25 as its effective components (claim
26), and a medical compound used for curing patients who need
suppression of the function or the expression of a protein acting
as a sensor of extracellular sodium ion level, and containing the
protein according to any one of claims 9 to 11 or the material that
suppresses the function or the expression of a protein acting as a
sensor of extracellular sodium ion level according to claim 25 as
its effective components (claim 27).
BRIEF EXPLANATION OF DRAWINGS
[0016] The patent or application file contains at least one drawing
executed in color. Copies of this patent or patent application
publication with color drawing(s) will be provided by the Office
upon request and payment of the necessary fee.
[0017] FIG. 1 is a view showing a gene map of Na.sub.v2 knockout
mice of the present invention (a), the result of Southern blot
technique (b), genomic PCR (c) and Western blot technique (d) of
genomic DNA.
[0018] FIG. 2 is a view showing lacZ-expressing areas in embryos,
dorsal root ganglia and the thoratic regions of Na.sub.v2 knockout
mice of the present invention.
[0019] FIG. 3 is a view showing lacZ-expressing areas in the brains
of Na.sub.v2 knockout mice of the present invention.
[0020] FIG. 4 is a view showing the result of the influence of
dehydration on the expression of a nuclear protein, Fos, in
Na.sub.v2 knockout mice of the present invention.
[0021] FIG. 5 is a view showing the result of the influence of
mouse Na.sub.v2 channel deficiency of the present invention to
water and salt intake of mice.
[0022] FIG. 6 is a view showing the result of responses to various
tastant stimuli in the chorda tympani nerve of Na.sub.v2 knockout
mice of the present invention.
[0023] FIG. 7 is a view showing the result of the measurement of
preference ratio for 0.3 M NaCl solution and total fluid intake of
Na.sub.v2 knockout mice of the present invention before and after
24-h dehydration.
[0024] FIG. 8 is a view showing the result of the sodium-depletion
induced salt appetite test for Na.sub.v2 knockout mice of the
present invention.
MODE FOR CARRYING OUT THE INVENTION
[0025] The null mutant non-human animal of the present invention is
not particularly limited, any non-human animal showing salt intake
behavior similar to wild-types under water-sufficient conditions
and showing much more intakes of hypertonic saline compared with
wild-types under water- and salt-depleted conditions will suffice,
however, the null mutant non-human animal whose function of
Na.sub.v2 genes is deficient on its chromosome is exemplified as a
concrete example of such non-human animal. "Much more intakes of
hypertonic saline compared with wild-type animals under water- and
salt-depleted conditions" mentioned here means that, for example,
in case of mice, the intake behavior in which the intake amount of
0.3 M saline after 24-h dehydration increases by 1.5-times or more,
preferably by 2-times or more compared with that of the wild-type
animals, preferably the littermate wild-type animals. Further, "the
null mutant non-human animal whose function of Na.sub.v2 genes is
deficient on its chromosome" means the non-human animal whose
endogenous genes that code for Na.sub.v2 are inactivated by its
destruction, deficiency, substitution or the like, so that the
animal has lost its function of expressing Na.sub.v2, and a rodent
such as a mouse or a rat and the like is exemplified as a concrete
example of the non-human animal, however, the non-human animal is
not limited to the exemplification. In following explanation, a
mouse is cited as an example of the non-human animal.
[0026] Any constructing method of Na.sub.v2 knockout mice will
suffice as long as it can construct the knockout mice that have
lost the function of expressing Na.sub.v2. For instance, the
following method is exemplified; the genomic DNA library of mice is
screened by using cDNA that codes for rat NaG, which is the species
counterpart of mice Na.sub.v2, as a probe, then an Na.sub.v2 gene
of genomic DNA is isolated, subsequently a targeting vector is
constructed by inserting a marker gene such as neo gene or the like
into the exon of Na.sub.v2, and thus constructed vector is induced
to ES cells by electroporation method, then homologously recombined
ES cells are selected, and germ line chimeric mice are constructed
with this ES cells strain, and they are intercrossed with the
wild-type mice, then the heterozygous mutant mice (F1: first filial
generation) are obtained, and by intercrossing of those
heterozygous mutant mice, wild-type mice, which are littermates of
Na.sub.v2 knockout mice generated according to Mendelian ratio, can
be generated,.
[0027] The protein acting as a sensor of extracellular sodium ion
level of the present invention is not particularly limited as long
as it acts as a sensor of sodium ion level in nerve cells of the
brain. For example, Na.sub.v2 shown in Seq. ID No. 3 (GenBank
accession number: L36179) or a protein comprised of amino acid
sequence where one or a few amino acids are deficient, substituted,
or added in amino acid sequence shown in Seq. ID No. 3 and acts as
a sensor of extracellular sodium ion level, or a recombined protein
of said proteins are concretely exemplified. Said protein acting as
a sensor of extracellular sodium ion level can be prepared based on
the DNA sequence information and the like by publicly known
methods.
[0028] The genes of the invention that code for a protein acting as
a sensor of extracellular sodium ion level include the gene that
codes for Na.sub.v2 shown in Seq. ID No. 3 in the sequence listing,
for instance, Na.sub.v2 gene shown in Seq. ID No. 2, gene DNA that
codes for a protein comprised of amino acid sequence where one or a
few amino acids are deficient, substituted, or added in amino acid
sequence shown in Seq. ID No. 3, and the DNA that hybridizes with
these gene DNAs under the stringent conditions and codes for the
protein acting as a sensor of extracellular sodium ion level. These
genes can be prepared based on the DNA sequence information and the
like, for example with genomic library of mice constructed from
cell line R1, 129/SvJ mice gene library or the like, by publicly
known methods.
[0029] It is also possible to obtain DNA of the target that codes
for a protein acting as a sensor of extracellular sodium ion level,
such as human Na.sub.v2.1 (GenBank accession number: M91556), rat
NaG/SCL11 (GenBank accession number: Y09164) and the like, which
have the same effect as Na.sub.v2 genes, by hybridizing DNA library
derived from mice under the stringent conditions, with a base
sequence shown in Seq. ID No. 2 or its complimentary sequence and a
part or whole of those sequences as a probe, and subsequent
isolation of DNA that hybridizes said probe. As conditions of the
hybridization to obtain said DNA, for instance, a hybridization at
42.degree. C. and a rinsing treatment in buffer including
1.times.SSC and 0.1% SDS at 42.degree. C., and more preferably, a
hybridization at 65.degree. C. and a rinsing treatment in buffer
including 1.times.SSC and 0.1% SDS at 65.degree. C. are
exemplified. As factors influential in the stringency of a
hybridization, there are various factors besides the
above-mentioned temperature condition, and it is possible for a
person skilled in the art to realize a same stringency as the
above-illustrated stringency of the hybridization by combining
those various factors appropriately.
[0030] The fusion protein of the present invention is defined as a
protein constructed by combining a protein acting as a sensor of
extracellular sodium ion level, such as Na.sub.v2 and the like, and
a marker protein and/or a peptide tag. As a marker protein, any of
conventionally known marker protein will suffice, for example,
alkaline phosphatase, Fc region of antibodies, HRP, GFP and the
like are concretely exemplified, and as a peptide tag of the
present invention, conventionally known peptide tag such as Myc
tag, His tag, FLAG tag, GST tag and the like are concretely
exemplified. Said fusion proteins can be constructed by a usual
method, and are useful as an investigational reagent in the field
concerned such as the purification of a protein acting as a sensor
of extracellular sodium ion level utilizing the affinity between
Ni-NTA and His tag, the detection of said protein, the
quantification of an antibody to said protein and the like.
[0031] As an antibody of the present invention that specifically
combines with a protein acting as a sensor of extracellular sodium
ion level, an immunospecific antibody such as a monoclonal
antibody, a polyclonal antibody, a chimeric antibody, a single
stranded antibody, a humanized antibody and the like are concretely
exemplified. Though these antibodies can be constructed by a usual
method with the above-mentioned protein acting as a sensor of
extracellular sodium ion level as an antigen, a monoclonal antibody
is more preferable among them because of its specificity. Said
antibody that specifically combines with a protein acting as a
sensor of extracellular sodium ion level, such as a monoclonal
antibody or the like, is useful, for instance, for the diagnosis of
diseases caused by mutation or deficiency of Na.sub.v2 such as
chronic diseases of human caused by excessive intake of salt, and
for elucidation of molecular mechanism of a protein such as
Na.sub.v2 or the like acting as a sensor of extracellular sodium
ion level.
[0032] An antibody to a protein acting as a sensor of extracellular
sodium ion level is developed by administering fragments containing
a protein acting as a sensor of extracellular sodium ion level or
its epitope, or cells that express said protein on the surface of
the membrane to animals (preferably excluding human) with usual
protocol. For instance, a polyclonal antibody can be prepared by
immunizing a rabbit or the like with an antigen peptide as an
immmunogen, constructing antiserum by a usual method, and then
purifying the constructed antiserum by a column in which the
peptide used as the immunogen is fixed. Further, in preparation of
a monoclonal antibody, any method that brings antibodies developed
by cultured materials of continuous cell line, such as hybridoma
method (Nature 256, 495-497, 1975), trioma method, human B-cell
hybridoma method (Immunology Today 4, 72, 1983), and EBV-hybridoma
method (MONOCLONAL ANTIBODIES AND CANCER THERAPY, pp. 77-96, Alan
R. Liss, Inc., 1985) can be used. Followings are the explanation of
the method of constructing a monoclonal antibody that specifically
combines with Na.sub.v2 derived from mice, that is, an
anti-mNa.sub.v2 monoclonal antibody, with an example of Na.sub.v2
derived from mice as a protein acting as a sensor of extracellular
sodium ion level.
[0033] The above-stated anti-mNa.sub.v2 monoclonal antibody can be
developed by cultivating an anti-mNa.sub.v2 monoclonal antibody
developing hybridoma in vivo or in vitro by a usual method. For
instance, said anti-mNa.sub.v2 monoclonal antibody is available
through cultivation inside abdominal cavity of rodents, preferably
mice or rats, in vivo, and through cultivation on a culture medium
for animal cells in vitro. As examples of a medium for cultivating
hybridoma in vitro, some cell culture mediums, such as RPMI1640,
MEM or the like, which contain antibiotics like penicillin,
streptomycin or the like are exemplified.
[0034] Anti-mNa.sub.v2 monoclonal antibodies developing hybridoma
can be constructed, for example, by the following procedures.
First, BALB/c mice are immunized by using Na.sub.v2 derived from
mice or the like, then spleen cells and mouse NS-1 cells (ATCC
TIB-18) of the immunized mice are fused by a usual method, and then
screened by immunofluorescence staining pattern. As methods of
separating and purifying said monoclonal antibodies, any method
generally used to purify a protein will suffice, and liquid
chromatography such as affinity chromatography and the like are
concretely exemplified.
[0035] In order to develop a single stranded antibody to a protein
acting as a sensor of extracellular sodium ion level of the present
invention, the preparation method of single stranded antibodies
(U.S. Pat. No. 4,946,778) can be applied. Further, in order to
express a humanized antibody, it is possible to use transgenic
mice, other mammalian animals or the like, and to isolate and
identify the clones that express a protein acting as a sensor of
extracellular sodium ion level with the above-mentioned antibodies,
and to purify the polypeptide by affinity chromatography. An
antibody to a protein acting as a sensor of extracellular sodium
ion level is useful for elucidating the molecular mechanism of a
protein acting as a sensor of extracellular sodium ion level.
[0036] It is possible to analyze the function of said protein
acting as a sensor of extracellular sodium ion level by using the
above-mentioned antibodies such as anti-mNa.sub.v2 monoclonal
antibodies and the like labeled with fluorescent materials like
FITC (fluorescein isothiocyanate), tetramethylrhodamine
isothiocyanate or the like; with radioisotopes such as .sup.125I,
.sup.32P, .sup.14C, .sup.35S, .sup.3H or the like; or with enzymes
like alkaline phosphatase, peroxidase, .beta.-galactosidase,
phycoerythrin or the like; or by using fusion proteins where
anti-mNa.sub.v2 monoclonal antibodies are fused with fluorescence
emission proteins such as green fluorescent protein (GFP) or the
like. Examples of the immunoassays include RIA method, ELISA
method, fluorescent antibody technique, plaque method, spot method,
hemagglutination reaction method, Ouchterony method and the
like.
[0037] This invention relates to a host cell which contains an
expression system that can express a protein acting as a sensor of
extracellular sodium ion level. The gene that codes for a protein
acting as a sensor of extracellular sodium ion level can be
introduced into a host cell by a number of methods described in
standard laboratory manuals by Davis et al. (BASIC METHODS in
MOLECULAR BIOLOGY, 1986), and by Sambrook et al. (MOLECULAR
CLONING: A LABORATORY MANUAL, 2nd Ed., Cold Spring Harbor
Laboratory Press, Cold Spring Harbor, N.Y., 1989), and the like.
Examples of those methods include calcium phosphate transfection,
DEAE-dextran-mediated transfection, transvection, microinjection,
cationic liposome-mediated transfection, electroporation,
transduction, scrape loading, ballistic introduction and infection.
Examples of the host cells include bacterial procaryotic cells such
as Escherichia coli, Streptomyces, Bacillus subtilis,
Streptococcus, Staphylococcus and the like; fungous cells such as
yeast, Aspergillus and the like; insect cells such as drosophila
S2, spodptera Sf9 and the like; and animal or plant cells such as L
cells, CHO cells, COS cells, HeLa cells, C127 cells, BALB/c3T3
cells (including mutant strains deficient in dihydrofolate
reductase, thymidine kinase or the like), BHK21 cells, HEK293
cells, Bowes melanoma cells, oocytes and the like.
[0038] As the expression system, any expression system that can
express a protein acting as a sensor of extracellular sodium ion
level in a host cell will suffice. Examples of the expression
system include expression systems derived from chromosome, episome
and virus, for example, vectors derived from bacterial plasmid,
yeast plasmid, papovavirus like SV40, vaccinia virus, adenovirus,
chicken pox virus, pseudorabies virus, or retrovirus, vectors
derived from bacteriophage, transposon, and the combination of
these, for instance, vectors derived from genetic factors of
plasmid and of bacteriophage such as cosmid or phagemid. These
expression systems may contain regulatory sequence that acts not
only as a promoter but also as a controller of expressions.
[0039] A host cell that contains the above-mentioned expression
system, cell membrane of said host cell, and a protein acting as a
sensor of extracellular sodium ion level which is obtainable by the
cultivation of said host cell can be used in the screening method
of the present invention as hereinafter described. For example, the
method of F. Pietri-Rouxel et al. (Eur. J. Biochem., 247,
1174-1179, 1997) or the like can be used as the method to obtain
cell membranes, and publicly known methods including ammonium
sulfate or ethanol precipitation, acid extraction, anion or cation
exchange chromatography, phosphocellulose chromatography,
hydrophobic-interaction chromatography, affinity chromatography,
hydroxyapatite chromatography, and lectin chromatography,
preferably high-speed liquid chromatography can be used to pick up
said protein acting as a sensor of extracellular sodium ion level
from cell cultured material and purify it. As columns used for
affinity chromatography, in particular, there are columns to which
an antibody to a protein acting as a sensor of extracellular sodium
ion level such as an anti-Na.sub.v2 monoclonal antibody and the
like is bound, or in case that normal peptide tag is added to said
protein such as Na.sub.v2 or the like acting as a sensor of
extracellular sodium ion level, there are columns to which
materials having affinity to the peptide tag are bound. These
proteins acting as sensors of extracellular sodium ion level can be
obtained by using these columns.
[0040] In the present invention, transgenic non-human animal that
excessively expresses a gene that codes for a protein acting as a
sensor of extracellular sodium ion level is defined as non-human
animal that produces larger amount of a protein acting as a sensor
of extracellular sodium ion level than wild-type non-human animal
does. Though concrete examples of a non-human animal of the present
invention include rodents, such as rabbits, mice, rats and the
like, a non-human animal of the present invention is not limited to
these animals.
[0041] Homozygous non-human animals generated according to
Mendelian ratio include excessive expression type that excessively
expresses a protein acting as a sensor of extracellular sodium ion
level and the littermate wild-type, and it is possible to carry out
precise comparative experiments in individual level by using the
excessive expression types and the littermate wild-types of these
homozygous non-human animals at the same time. Therefore, it is
preferable to use animals of the same species, more preferably the
littermates, as the wild-type non-human animals, in other words,
the non-human animals that excessively express a gene that codes
for a protein acting as a sensor of extracellular sodium ion level
together in, for example, the screening hereinafter described in
the present invention. The generating method of the non-human
animals that excessively express a gene that codes for a protein
acting as a sensor of extracellular sodium ion level will be
explained below, with an example of transgenic mice of a protein
acting as a sensor of extracellular sodium ion level.
[0042] The transgenic mice of a protein acting as a sensor of
extracellular sodium ion level can be generated in following
procedures. A transgene is constructed by fusing promoters such as
chicken .beta.-actin, mouse neurofilament, SV40 or the like, and
poly A or introns such as rabbit .beta.-globin, SV40 or the like
with cDNA that codes for a protein such as Na.sub.v2 or the like
acting as a sensor of extracellular sodium ion level. The transgene
is microinjected in the pronucleus of a fertilized egg of a mouse,
and the egg cell is cultured, then transplanted to the oviduct of a
recipient mouse. After rearing up the recipient animal, baby mice
that have the above-mentioned cDNA are selected from the mice born
from the recipient animal. Thus transgenic mice can be generated.
The baby mouse that has cDNA can be selected by extracting crude
DNA from a tail or the like of a mouse, then carrying out methods
like dot hybridization using a gene that codes for a protein acting
as a sensor of extracellular sodium ion level as a probe, PCR
method using a specific primer and the like.
[0043] By using a protein acting as a sensor of extracellular
sodium ion level, a gene that codes for said protein, a fusion
protein created by combining a protein acting as a sensor of
extracellular sodium ion level and a marker protein and/or a
peptide tag, an antibody to a protein acting as a sensor of
extracellular sodium ion level, a host cell which contains an
expression system that can express a protein acting as a sensor of
extracellular sodium ion level, a non-human animal which
excessively expresses a gene that codes for a protein acting as a
sensor of extracellular sodium ion level, a null mutant non-human
animal showing salt intake behavior similar to that of the
wild-type animals under water-sufficient conditions and showing
much more intakes of hypertonic saline compared with the wild-type
animals under water- and salt-depleted conditions, a cell that
expresses a protein acting as a sensor of extracellular sodium ion
level, or the like, it becomes possible to screen a material that
promotes or suppresses the function of a protein acting as a sensor
of extracellular sodium ion level or a material that promotes or
suppresses the expression of a protein acting as a sensor of
extracellular sodium ion level. What obtained by this screening
could be a suppressant, a preventive, or a remedy for chronic
diseases of human resulted from excessive intake of salt, or
substances useful for diagnosis and cure of the diseases resulted
from deficiency or abnormality of a protein acting as a sensor of
extracellular sodium ion level or the like.
[0044] Examples of said screening methods include a method with
cells that express a protein acting as a sensor of extracellular
sodium ion level and a subject material; a method with null mutant
non-human animals of the present invention showing salt intake
behavior similar to that of the wild-type animals under
water-sufficient conditions and showing much more intakes of
hypertonic saline compared with the wild-type animals under water-
and salt-depleted conditions or transgenic non-human animals which
excessively express a gene that codes for a protein acting as a
sensor of extracellular sodium ion level, and the subject
material.
[0045] As a screening method with cells that express a protein
acting as a sensor of extracellular sodium ion level and a subject
material is, a method wherein cells that express a protein acting
as a sensor of extracellular sodium ion level and a subject
material are brought into contact, and then the change of the
function or the expression of a protein acting as a sensor of
extracellular sodium ion level is measured/evaluated is
exemplified.
[0046] Concrete examples of a screening method with the null mutant
non-human animals showing salt intake behavior similar to that of
the wild-type animals under water-sufficient conditions and showing
much more intakes of hypertonic saline compared with the wild-type
animals under water- and salt-depleted conditions or the transgenic
non-human animals which excessively express a gene that codes for a
protein acting as a sensor of extracellular sodium ion level and
the subject material include; a method wherein nerve cells obtained
from the null mutant non-human animals showing salt intake behavior
similar to that of the wild-type animals under water-sufficient
conditions and showing much more intakes of hypertonic saline
compared with the wild-type animals under water- and salt-depleted
conditions, or from the transgenic non-human animals which
excessively express a gene that codes for a protein acting as a
sensor of extracellular sodium ion level are brought into contact
with a subject material in vitro, and then the change of the
function or the expression of said protein is measured/evaluated; a
method wherein saline is administrated to said null mutant
non-human animals or to said transgenic non-human animals
beforehand, then the nerve cells obtained from said non-human
animals are cultured in the presence of the subject material, and
the change of the function or the expression of said protein is
measured/evaluated; a method wherein saline and a subject material
are administrated to said null mutant non-human animals or to said
transgenic non-human animals beforehand, then the change of the
function or the expression of said protein in the nerve cells
obtained from said non-human animals is measured/evaluated; a
method wherein saline and a subject material are administrated to
said null mutant non-human animals or to the transgenic non-human
animals beforehand, then the change of the function or the
expression of said protein in the non-human animals is
measured/evaluated.
[0047] In measuring and evaluating the change of the function or
the expression of a protein acting as a sensor of extracellular
sodium ion level, it is preferable to evaluate/compare with the
measured value of the wild-type non-human animals, in particular,
of the littermate wild-type non-human animals, as control, because
it offsets the dispersion caused by the difference between
individuals. The function of a protein acting as a sensor of
extracellular sodium ion level is to regulate sodium level of body
fluid in vivo, that is, to act as a sensor of extracellular sodium
ion level. Although concrete examples of the change of said
function include the change of the function in the sensory circuits
for body fluid osmolarity, the change in preference-aversion
response to the intake of water and salt and the like, the change
of the function is not limited to these examples.
[0048] The medical compounds of the present invention are not
limited particularly as long as the medical compounds contain said
protein of the present invention that acts as a sensor of
extracellular sodium ion level, or materials that promote or
suppress the function of a protein acting as a sensor of
extracellular sodium ion level, or materials that promote or
suppress the expression of a protein acting as a sensor of
extracellular sodium ion level as their effective components, and
these medical compounds can be used for the treatment of the
patients who need promotion of the function or enhancement of the
expression of a protein acting as a sensor of extracellular sodium
ion level, or the patients who need suppression of the function or
the expression of a protein acting as a sensor of extracellular
sodium ion level.
[0049] The present invention will be explained in detail with
embodiments below, but the technological scope of the present
invention is not limited to these embodiments.
[0050] [Construction of a Targeting Vector]
[0051] In order to construct a targeting vector, genomic fragments
of mice containing protein-coding exons 1, 2 and 3 were cloned by
NaG/SCL11 probe of rats. Nine independent genomic clones were
isolated from mouse genomic libraries (donated by Dr. Mori, Osaka
Univ., Japan) prepared from a cell line R1, by hybridization with a
446-bp fragment of rat NaG cDNA (nucleotide residues 11-456
encompassing the first three coding exons: GenBank accession number
Y09164: Seq. ID No. 1). By Southern blot analysis using several
restriction enzymes, it has been confirmed that all these
overlapping clones were derived from a single genomic locus. The
hybridization-positive 3.2 and 3.7 kb HindIII fragments were
subcloned into pBluescript II SK (-) (Stratagene) and subjected to
DNA sequencing (the sequence is in GenBank under accession number
AF190472: Seq. ID No. 4). The 3.2 kb fragment contained
protein-coding exon 1 (13 bases of the 5' untranslated region and
the first 238 bases in the mouse Na.sub.v2 protein-coding sequence:
nucleotide residues 238-490 of GenBank accession number L36179) and
the 3.7 kb fragment contained exons 2 (nucleotide residues 491-609)
and 3 (nucleotide residues 610-701). The DNA sequence encoding the
three exons was identical to that of mouse Na.sub.v2.3 cDNA cloned
by Tamkun and coworkers (J. Biol. Chem. 269, 30125-30131(1994)).
The cloned genomic fragments showed identical restriction maps with
mouse genomic DNA on Southern blot analysis with four restriction
enzymes (BamH I, Bgl II, EcoR I and Hind III). This finding
indicates that mouse Na.sub.v2.3 is the species counterpart of rat
NaG. Accordingly, Na.sub.v2.3, NaG and SCL11 are designated as
Na.sub.v2.
[0052] In order to construct the targeting vector, the lacZ gene
was so designed that it would be inserted into the protein-coding
exon 1 of the mouse Na.sub.v2 gene and that the N-terminal twenty
amino-acid sequence of mouse Na.sub.v2 would be fused with
.beta.-galactosidase. In other words, the 12.5 kb Sal I fragment
containing the three exons was inserted into the Xho I site of
pDT-A (Anal. Biochem. 214, 77-86 (1993)), then the Sal I-Xho I
fragment of the lacZ-neo cassette was introduced into the
endogenous Xho I site located in exon 1 (see FIG. 1a). This results
in the expression of a protein that fuses the first 20 amino acids
of the mouse Na.sub.v2 protein with the N-terminus of
.beta.-galactosidase. The original genomic structure of mouse
Na.sub.v2 gene was not modified except for the insertion of the
lacZ-neo cassette to make sure that the lacZ gene is expressed in
place of the mouse Na.sub.v2 gene in the targeted mice. An EcoR I
linker was inserted beforehand into the 5' terminus of the lacZ-neo
cassette to utilize it as an exogenous restriction site in Southern
blot screening analysis. FIG. 1a shows restriction maps of the
targeting vector (top), mouse Na.sub.v2 gene locus of wild-types
(middle), and recombinant gene locus (bottom). In FIG. 1a,
restriction sites B, Bg, E, H, and X represent BamH I, Bgl II, EcoR
I, Hind III and Xho I respectively.
[0053] [Generation of Na.sub.v2 Knockout Mice]
[0054] The above-mentioned filamentous shaped targeting vector was
induced into ES cells (R1 cell line derived form 129/SV mouse) by
an electroporation method. According to the method described in the
paper (Neurosci. Lett. 247, 135-138 (1998)), neomycin-resistant ES
clones were selected by G418, and screening of the targeted clones
were performed. Homologous recombination was verified by Southern
blot analysis using EcoR I digestion with probe 1 (see FIG. 1a; the
0.3 kb EcoR I-Xba I fragment located about 8 kb upstream from the
Xho I site in exon 1). The selected clones were checked using probe
2 (the 0.6 kb Pst I fragment derived from the neo gene). The
targeted locus was verified by genomic PCR using one sense primer
(primer 1, ATGTTGACTTCCCCAGAGCC in the 5'-terminal region of exon
1, Seq. ID No. 5) and two antisense primers (primer 2,
AACCAGGCAAAGCGCCATTC in the 5'-terminal region of lacZ, Seq. ID No.
6: primer 3, CATCTTCCAAGGGCTCTGACA in the 3'-terminal region of
exon 1, Seq. ID No. 7). PCR amplification was carried out in two
stages with EX-Taq polymerase (Takara) according to the
manufacturer's protocol using a programmable thermal cycler (first
stage; 95.degree. C. for 5 minutes, 60.degree. C. for 1 minute,
72.degree. C. for 1 minute: second stage; 95.degree. C. for 30
seconds, 60.degree. C. for 30 seconds, 72.degree. C. for 1
minute).
[0055] Two out of 98 ES clones, which were identified to have the
correct homologous recombinant allele, were used for injection into
eight-cell stage C57BL/6J mouse embryos. The injected embryos were
cultured in M16 medium overnight up to blastocysts, and seven to
ten blastocysts were transplanted into the uterus of a recipient
ICR mouse. The male chimeric mice thus obtained were mated with
C57BL/6J females, and heterozygous mice (F1: first filial
generation) were generated from littermates, and this heterozygous
mutant mice were intercrossed subsequently in order to obtain
homozygous mice, then Na.sub.v2 deficient mice, which were produced
according to Mendelian ratio, were generated.
[0056] The null mutant animals (mouse Na.sub.v2.sup.-/-) were
healthy, fertile and apparently normal. The genotypic analysis of
458 four-week-old offspring obtained from breeding heterozygous
animals showed an approximately Mendelian ratio between wild-type
(29.5%, n=135), heterozygous mutant (48.2%, n=221) and homozygous
mutant (22.3%, n=102) animals. This suggests that embryonic
development and body functions were not significantly impaired in
either heterozygous or homozygous mutant animals. It was reported
that acute and transient expression of mouse Na.sub.v2 was induced
perinatally to the uterine smooth muscle (J. Biol. Chem. 269,
30125-30131 (1994), Am. J. Physiol. 270, C688-696 (1996)). It
should be noted that pups were delivered normally in
Na.sub.v2.sup.-/- mice. The pattern of lacZ expression in the null
mutants was identical to that in the heterozygous mutants except
for the intensity of the expression, suggesting that deficiency of
mouse Na.sub.v2 does not affect the differentiation or viability of
the mouse Na.sub.v2-expressing cells.
[0057] FIG. 1b shows the result of Southern blot analysis in which
samples of genomic DNA were derived from tails of wild-type (+/+),
heterozygous (.+-.), and homozygous (-/-) mice, and then membranes
blotted with genomic DNA digested with EcoR I were hybridized with
said probe 1 located on the 5' side of the targeting vector. The
sizes for the wild-type (18 kb) and recombinant (10 kb) genotypes
are shown on the right of FIG. 1b. FIG. 1c shows the result of
genomic PCR analysis of wild-type (+/+), heterozygous (.+-.), and
homozygous (-/-) mutant mice. The sizes for the wild-type (200 bp)
and recombinant (400 bp) genotypes are shown on the right of FIG.
1c.
[0058] [Confirmation of Non-Expression of Na.sub.v2 in Na.sub.v2
Knockout Mice]
[0059] The mouse Na.sub.v2 protein expression in the mutant mice
was examined by Western blot analysis. Lung tissue samples of each
wild-type (+/+), heterozygous (.+-.), and homozygous (-/-) mice
were prepared according to the methods of Knittle et al. (Am. J.
Physiol. 270, C688-696 (1996)). SDS-polyacrylamide gel
electrophoresis and immunoblotting were carried out according to
the method described in the paper (Neurosci. Lett. 247, 135-138
(1998)). Anti-mouse-Na.sub.v2.3 antiserum (a generous gift from Dr.
M. Tumkun, Colorado State Univ., CO) was used at a 1:500 dilution
in PBS. The immunoblots were incubated with several non-immune sera
to verify that it was not non-specific combination. The results are
shown in FIG. 1d. The position of Na.sub.v2 protein (220 kDa) is
indicated on the right of FIG. 1d. The sodium channel gave a broad
signal, since Na.sub.v2 protein is highly glycosilated and readily
aggregates even in the SDS-containing buffer. Compared with
wild-type mice, about a half of the amount of mouse Na.sub.v2
protein in heterozygous mutant (Na.sub.v2.sup..+-.) mice, and no
mouse Na.sub.v2 protein in homozygous mutant (Na.sub.v2.sup.-/-)
mice was detected in lung membrane preparations. It is indicated
that the allele was a null mutation because mouse Na.sub.v2 protein
was not expressed.
[0060] [Confirmation of the Expression of lacZ in Na.sub.v2
Knockout Mice by X-Gal Staining]
[0061] Embryos were fixed by immersion in 3.5% formaldehyde in PBS
for 1 hour at room temperature, and then cut midsagittally with a
razor. FIG. 2a shows X-Gal staining of a whole-mount mouse
Na.sub.v2.+-. embryo at embryonic day 15 (E15). Intensive
.beta.-galactosidase activity was observed in the trigeminal
ganglia (pointed by the arrowhead in FIG. 2a) and dorsal root
ganglia (pointed by the arrow in FIG. 2a) (see reference photograph
1). In this E15 mouse, lacZ-expression was evident also in the lung
(pointed by the asterisk). In these organs, the expression of lacZ
persisted into adulthood. When dorsal root ganglia were cut into
thin sections after X-Gal staining, .beta.-galactosidase activity
was detected in spinal sensory neurons with various cellular
diameters. An X-Gal stained cryostat tissue section of dorsal root
ganglion of postnatal day 2 Na.sub.v2.sup..+-. mouse was shown in
FIG. 2b (see reference photograph 1). The expression of lacZ was
confined to the somata of neurons within dorsal root ganglion
(nerve tracts are shown by asterisk in FIG. 2b), and not detected
in axons. A similar pattern of lacZ expression was observed in
tissue sections of the trigeminal ganglia. A cryostat section of
adult sympathetic nerve trunk in the thoracic region is shown in
FIG. 2c (see reference photograph 1). Based on the appearance,
distribution, and size of the cell bodies, the numerous intensely
stained cells are likely to be Schwann cells. The expression of
lacZ was also observed in cardiac autonomic nerves and lingual
nerves. These patterns of lacZ expression agreed well with the
results of rat Na.sub.v2 and mouse Na.sub.v2 expressions (Proc.
Natl. Acad. Sci. USA89, 7272-7276(1992), FEBS Lett. 400, 183-187
(1997), Glia, 21, 269-276 (1997)). This indicates that the lacZ
gene expression is duly under the control of the regulatory regions
of mouse Na.sub.v2 gene. In FIG. 2c, the arrowheads identify the
somata of Schwann cells, and scale bar=50 .mu.m.
[0062] [Physiological roles of Na.sub.v2]
[0063] In order to examine the physiological roles of mouse
Na.sub.v2, the lacZ-expression was surveyed throughout central
nervous system (CNS) using brains of Na.sub.v2.sup..+-. and
Na.sub.v2.sup.-/- mice. Postnatal animals were perfused under
pentobarbital anesthesia first with PBS and then with the fixative.
The fixed brains were cut coronally at 2 mm thick or sagittally
with a razor. Samples were rinsed twice with PBS and incubated
overnight in PBS containing 1 mg/ml X-Gal, 5 mM
K.sub.3Fe(Cn).sub.6, 5 mM k.sub.4Fe(CN).sub.6, 2 mM MgCl.sub.2, and
0.2% NP-40 at 37.degree. C. For inmnunostaining, some X-Gal stained
slices were cut further into coronal sections at 14 .mu.m thick
with a cryostat microtome and mounted onto gelatin-coated slides.
With rabbit polyclonal antibodies to anti-neurofilament 200 (Sigma,
N-4142) or to anti-glial fibrillary acidic protein (GFAP) (Santa
Cruz Biochemistry, sc-6170), immunostaining was performed
(Neurosci. Lett. 247, 135-138 (1998)). FIG. 3 shows that mouse
Na.sub.v2 was expressed in specialized neurons and ependymal cells
in the adult CNS (see reference photograph 2).
[0064] In FIG. 3, lacZ expression in the CNS of Na.sub.v2.sup..+-.
(FIG. 3a-e) and Na.sub.v2.sup.-/- (FIG. 3f) mutant mice were shown.
Fixed adult brains were cut coronally (FIG. 3a, b, d, e and f) or
midsagittally (FIG. 3c) at 2 mm and then stained with X-Gal. In
(FIG. 3c), the skull under the brain was not removed. In (FIG. 3e),
homozygous mutant mice were used for the analysis to detect the
locus of low level expression. Explanations of the abbreviations in
FIG. 3 are as follows: AH, anterior hypothalamic area; MH, medial
habenular nucleus; ME, median eminence; OVLT, organum vasculosum
laminae terminalis; MPO, medial preoptic area; DMH, dorsomedial
hypothalamus; IPDM, interpeduncular nucleus of the dorsomedial
part; MMR, medial part of the median raphe; NHP, neurohypophysis;
SFO, subfornical organ; CX, cerebral cortex; BLA, basolateral
amygdala. In (FIG. 3c), OVLT was removed from the central nervous
system and attached to the skull. The coronal semi-whole-mount
brains were cut 50 .mu.m thick using cryostat microtome and then
stained with anti-neurofilament polyclonal antibodies (FIG. 3g and
h), anti-GFAP polyclonal antibodies (FIG. 3i), or cresyl violet
(FIG. 3j). Brown signals are the site that reacted with the
antibodies. The samples are AH (FIG. 3g), SFO (FIG. 3h and i) and
ME (FIG. 3j). Arrowheads indicate double positive neurons. The
asterisk in FIG. 3j indicates the third ventricle. The dorsal side
is toward the top of the panels. Scale bar: FIG. 3g to FIG. 3h=30
.mu.m; FIG. 3j=100 .mu.m.
[0065] As shown in FIG. 3, clusters of lacZ expression were limited
to specific loci in the central nervous system (FIG. 3a-f): MPO,
AH, DMH, IPDM, MMR, MeV, MH, ME, SFO, OVLT and NHP, ME, SFO, OVLT
and NHP are known as the circumventricular organs (CVOs) having
unusual dense and permeable capillary networks that facilitate
secretion of substances into blood or penetration of substances
into important tissue (FASEB J, 7, 678-686 (1993)). Relatively weak
lacZ expression was detected in CX and BLA in Na.sub.v2.sup..+-.
mice. The intensity of the lacZ expression in these areas was more
evident in Na.sub.v2.sup.-/- mice (FIG. 3f). To examine the
cell-types expressing lacZ, the brains were stained with X-Gal and
cut into tissue sections with a cryostat microtome and subsequently
immunostained with anti-neurofilament polyclonal antibodies or
anti-glial fibrillary acidic protein (GFAP) polyclonal antibodies,
or stained with cresyl violet. Most of the cells expressing lacZ
were positive for neurofilament in the MPO, AH (FIG. 3g), IPDM,
MMR, MH and MeV. GFAP-positive cells were negative for the lacZ
expression, suggesting that astrocytes are negative for mouse
Na.sub.v2.
[0066] The distribution of lacZ-expressing cells in the CVOs was of
particular interest. In the ME, the lacZ-expressing cells lined the
floor of the third ventricle (FIG. 3j). This distribution
corresponds to the location of nonciliated ependymal cells. These
cells are thought to be tanycytes, which are characteristic cells
providing a morphological connection between cerebrospinal fluid
(CSF), nerve cells and blood vessels (Neuroscience 3, 277-283
(1978)). They are thought to be involved in exchange of substances
between the CSF and pericapillary space. The lacZ-positive cells
were sparsely distributed all over the SFO, and most of them were
co-localized with neurofilaments (FIG. 3h) and negative for GFAP
(FIG. 3i). Intensive lacZ-positive cells also populated lining the
entire third ventricle, suggesting that they are ependymal cells.
In the NHP, the X-Gal signals were densely clustered. They are
likely to correspond to so-called pituicytes (J. Exp. Biol. 139,
67-79 (1988)).
[0067] [Fos-immunohistochemistry]
[0068] Since analysis of the lacZ expression clearly demonstrated
that mouse Na.sub.v2 was expressed in the four CVOs and several
nuclei in the central nervous system and that the mouse
Na.sub.v2-expressing cells were thus diverse not only in tissue
distribution but also in cell types, it became difficult to obtain
a unified view of channel function or property. However, the four
CVOs are thought to be involved in body-fluid homeostasis (FASEB J,
7, 678-686 (1993), Annu. Rev. Physiol. 59, 601-619 (1997), Physiol.
Rev. 78, 583-686 (1997), Physiol. Rev. 58, 582-603 (1978), Ann. NY
Acad. Sci, 877, 258-280 (1999)). If the mouse Na.sub.v2 channel
functions in the sensory circuits for body-fluid osmolarity, it was
expected that the activity and gene expression in these organs
would be affected in the mouse Na.sub.v2 mutant mice. Therefore,
the effects of water deprivation on the central expression of Fos,
a nuclear protein and a marker of changes in neural activity in
response to the extracellular fluid balance in mice and rats, were
examined as follows.
[0069] The time course of changes in Fos-immunopositive cell
density in five regions of the brain (the medial preoptic nucleus
(MnPO), organum vasculosum laminae terminalis (OVLT), subfornical
organ (SFO), paraventricular nucleus (PVN), and supra optic nucleus
(SON)) under water-sufficient and water-depleted conditions were
examined with mice which were deprived of water for 0 h (n=4 for
mouse Na.sub.v2.sup.+/+, n=4 for mouse Na.sub.v2.sup.-/-, 12 h (n=5
and 5), 24 h (n=6 and 7), or 48 h (n=6 and 5). The mice were
perfused with the fixative as described above, and their brains
were immersed in the same fixative at 4.degree. C. overnight.
Brains were cut coronally into sections at 50 .mu.m thick on a
vibratome (Leica, VT1000S). Immunostaining was performed with a
goat anti-Fos polyclonal antibody (Santa Cruz Biochemistry,
sc-52-G) at a dilution of 1:1000 in PBS. Sections containing
regions of interest were chosen and the Fos-immunopositive nuclei
were enumerated. Each area was measured by using an image analysis
system (KS400 attached to Axiophoto 2). The number of nuclei
present per mm.sup.2 was determined in the above-mentioned five
regions of the brain. The results are shown in FIG. 4 (see
reference photograph 3).
[0070] FIG. 4a is typical examples of tissue sections containing
the OVLT derived from wild-type (+/+) and null mutant (-/-) mice
under water-sufficient or 24-h dehydrated condition. Scale bar=200
.mu.m. In FIG. 4b, mean numbers of Fos-immunopositive cells per
mm.sup.2 in subfornical organ (SFO), supra optic nucleus (SON),
paraventricular nucleus (PVN), organum vasculosum laminae
terminalis (OVLT) and the median preoptic nucleus (MnPO) during
water deprivation were plotted. The vertical bars indicate S. E.,
the asterisk shows that a significant difference (P<0.05)
between Na.sub.v2.sup.-/- and Na.sub.v2.sup.+/+ mice were revealed.
In the water-sufficient condition, Fos-immunopositive cells were
not detected in any region examined. At 12, 24 and 48 h after water
deprivation, number of cells with Fos-immunopositive nuclei was
remarkably increased in these regions in both Na.sub.v2.sup.-/- and
Na.sub.v2.sup.+/+ mice. However, in SFO and OVLT, approximately
two-fold increases in Fos-immunopositive nuclei were observed in
Na.sub.v2.sup.-/- mice as compared with in Na.sub.v2.sup.+/+ mice.
In the MnPO, PVN and SON, on the other hand, the rates of increase
in Fos-immunopositive cells were comparable between the two
groups.
[0071] [Behavioral Analysis]
[0072] The effect of mouse Na.sub.v2-channel deficiency on water
and salt intakes of mice was next examined. For the behavioral
study, the mutant mice were backcrossed with C57 BL/6J males. As a
result, it was verified that the behavior of F1 and F4 mice was
identical. The preferance-aversion behavior of the homozygous-,
heterozygous-mutant and wild-type littermates were measured by a
48-h two-bottle preference test. Mice were presented with a choice
between distilled water and a tasting solution for 48 h in their
home cage. For all behavioral studies, male mice at 12-24 weeks of
age were used. They are individually housed under constant room
temperature, humidity and 12/12 h light-dark cycle. The positions
of the two bottles were switched every 24 h to avoid side
preference. The total intake for each animal was measured and used
to calculate a preference ratio according to the following formula:
preference ratio=volume of tasting solution (ml)/total intake
volume of tasting solution and water (ml). The results are shown in
FIG. 5. Preference ratios for NaCl solutions with a series of
concentrations are shown in FIG. 5a, and that for three fundamental
tastants with fixed concentrations are shown in FIG. 5b. Homozygous
(-/-), heterozygous (.+-.) and wild-type (+/+) mice, five mice
each, were used here. FIG. 5a shows that the concentration
sensitivity to a series of NaCl solutions was comparable among the
three groups of mice under the condition satiated with water and
salt, and all the groups showed maximum preference to 0.1 M NaCl
and evasiveness to 0.3 M or higher concentration of NaCl. The null
mutants showed normal preferences to various tastants under the
condition satiated with water and salt. FIG. 5b shows that
preference ratios to sweet (0.5 M sucrose), sour (0.01 M HCl) and
bitter (0.02 M quinine hydrochloride) tasters were not different
among the groups.
[0073] [Electrophysiology]
[0074] To verify the normality in taste responses in the null
mutants, electrophysiological analysis was performed on the chorda
tympani nerve, which is known to be the nerve fiber responsible for
tasting NaCl. Male mice at 12-24 weeks of age were used (4
wild-type and 5 homozygous mice for the normal condition; 3
wild-type and 5 homozygous mice for the acute salt-appetite
condition). Each mouse was deeply anesthetized by an
intraperitoneal injection of sodium pentobarbital (60 mg/kg), then
tracheotomized and secured with a head holder. The chorda tympani
nerve was exposed, freed from surrounding tissues, and cut at the
point of its entry to the bulla. The whole bundle of the nerve was
dissected and lifted on a platinum wire recording electrode (0.1 mm
in diameter). An indifferent electrode was attached to nearby
tissue. The nerve activities were amplified, displayed on an
oscilloscope, and monitored with an audioamplifier. The amplified
signal was passed through an integrator with a time constant of 0.3
sec and was displayed on a slipchart recorder.
[0075] The taste solutions were 0.1 M NH.sub.4Cl, 0.1 M NaCl, 0.5 M
sucrose, 0.01 M HCl, 0.02 M Q-HCl, 0.1 M KCl and 0.1 M
CH.sub.3COONa (AcNa). These solutions were made up with distilled
water and 0.1 mM amiloride solution. Each solution and rinsing
water were applied to the anterior part of the tongue at room
temperature (25.+-.2.degree. C.). The tongue was rinsed for at
least 45 sec between successive stimuli. The magnitude of the whole
nerve response was measured as the height of the integrated
response from the baseline at 10 sec after onset of stimulation.
Recorded results of the chorda tympani response to various taste
stimuli are shown in FIG. 6a. The magnitudes of the responses to
various taste stimuli expressed as relative values with the
magnitude of the response of 0.1 M NH.sub.4Cl taken as the standard
are shown in FIG. 6b.
[0076] The neurophysiological responses to 0.02 M Q-HCl, and 0.1 M
CH.sub.3COONa were of similar intensity between the null-mutant and
wild-type mice. Responses to 0.1 M NaCl and 0.1 M CH.sub.3COONa
were decreased to the same degree by amiloride application in both
groups of mice, indicating that amiloride-sensitive channels in
taste buds in the mutant mice function normally. Similar results
were observed in the null-mutant and wild-type mice under the acute
salt appetite condition. This finding together with the normal
behavioral response to various tastants under water- and
salt-sufficient conditions (FIG. 5) shows that the taste reception
of the null mutants is not impaired.
[0077] Under the water-depleted condition, animals take in a large
quantity of water and avoid hypertonic saline to recover from the
hypertonic state. The preference to hypertonic saline (0.3 m NaCl)
before and after 24-h dehydration was examined. Before testing,
mice were trained to drink water from two bottles for one week. On
the day before dehydration, mice were presented with a choice
between water and 0.3 M NaCl at 10.00 h, and then measured for
fluid intake at 16.00 h. At 10.00 h on the next day, the bottles
were removed. Dry food was placed throughout the period of water
deprivation. After 24-h dehydration, the two bottles were returned
and fluid intakes were measured at 16.00 h. The results are shown
in FIG. 7. The null mutants showed an abnormal ingestion of
hypertonic saline under the water-depleted condition. Preference
ratio for 0.3 M NaCl solution (FIG. 7a) and total fluid intake
(FIG. 7b) were measured before and after 24-h dehydration. In this
experiment, n=6(+/+), 6(.+-.) and 6(-/-). Vertical bars in the FIG.
7 indicate S. E., and the asterisk shows that a significant
difference (P<0.05) between Na.sub.v2.sup.-/- and
Na.sub.v2.sup.+/+ mice were observed. In contrast to the wild-type
and heterozygous mutant mice, which showed markedly decreased
preference ratios to hypertonic saline after dehydration, the null
mutants showed no change in the preference ratio (FIG. 7a). Total
water intake (water plus 0.3 M NaCl) did not differ among the
groups both before and after 24-h dehydration. The total water
intake of all the groups showed more than a four-fold increase
after dehydration (FIG. 7b).
[0078] Blood was recovered from animals before or after dehydration
by decapitation, and then the concentrations of plasma electrolytes
were measured by using an electrolyte analyzer (9180, AVL
Scientific, GA). The electrolyte concentrations in the serum before
and after dehydration were normal in both wild-type and homozygous
mutant mice (n=6 each). The electrolyte concentrations in wild-type
and homozygous mutant mice before dehydration are as follows
respectively: 153.6.+-.0.6 and 153.0.+-.1.2 mM for Na.sup.+;
4.6.+-.0.1 and 4.7.+-.0.1 mM for K.sup.+; 118.5.+-.0.6 and
118.3.+-.0.9 mM for Cl.sup.-. The electrolyte concentrations in
wild-type and homozygous mutant mice after dehydration are as
follows respectively: 151.6.+-.0.8 and 150.+-.0.3 mM for Na.sup.+;
6.5.+-.0.2 and 6.7.+-.0.2 mM for K.sup.+; 116.0.+-.1.0 and
116.4.+-.0.8 mM for Cl.sup.-. This suggests that the null mutants
immediately excreted excessive amounts of sodium into urine, and
thus the renal function of null mutants works normally.
[0079] Furthermore, motivated salt appetite was induced by
intraperitoneal injection of a diuretic drug, furosemide, and
sodium-depleted food, then the sodium-depletion induced salt
appetite test was carried out in the following way. Before testing,
control measurements of water and 0.3 M NaCl intake were performed
for several days. At 10.00 h, mice were injected intraperitoneally
with 0.12 ml of normal saline (0.9% NaCl). The bottle of 0.3 M NaCl
was withdrawn and sodium-depleted food was supplied in place of a
normal diet. The second injection of normal saline was given at
16.00 h. On the following day, water and 0.3 M NaCl were presented
at 10.00 h and intakes of 0.3 M NaCl and water were measured at
12.00, 14.00 and 16.00 h. After that, a similar protocol with
furosemide injection (0.6 mg in 0.12 ml of normal saline) was
performed with sodium-depleted food in the same mice (acute
salt-appetite condition). Finally, the same protocol, except that
normal sodium-containing food was supplied, was performed to
evaluate the effect of sodium-depleted food. The results are shown
in FIG. 8.
[0080] The ingested volumes of water and 0.3 M NaCl are shown in
FIG. 8 in cumulative values for every 2 h. The results of the
behavioral study are shown in FIG. 8 as plotted mean cumulative
intakes of 0.3 M NaCl (right) and water (left) per 2 h starting
just after each experimental procedure as follows: a
sodium-depleted diet combined with normal saline injection (top), a
sodium-depleted diet combined with furosemide injection (middle),
and a sodium-contained diet combined with furosemide injection
(bottom). In this experiment, n=10 (+/+), 10 (.+-.) and 10 (-/-).
Vertical bars in FIG. 8 indicate S. E., and the asterisk shows that
a significant difference (P<0.05) between Na.sub.v2.sup.-/- and
Na.sub.v2.sup.+/+ mice were observed. As shown in FIG. 8, under the
control condition in which isotonic saline was injected in place of
a furosemide solution, the ingested volumes of water and 0.3 M NaCl
were comparable among the three groups (graphs at the top). Under
the acute salt appetite condition induced by furosemide injection
with a sodium-depleted diet, however, the null-mutants showed an
approximately two-fold increase in the ingestion of 0.3 M NaCl
compared with the wild-type and heterozygous mutant mice (right
graph at the middle). This abnormal ingestion of hypertonic saline
stopped when sodium-containing food was provided (graph at the
bottom).
[0081] [Na.sub.v2 Channel is a Sodium Concentration-Dependent
Sodium Channel]
[0082] It has been verified that Na.sub.v2 channel is a sodium
concentration-dependent sodium channel by following
experiments.
[0083] First, an anti-Na.sub.v2 antibody was constructed as
follows: a peptide comprised of an amino acid sequence
(SVSETVPIASGESDIK; Seq. ID No. 8), which exists in inter domain 2-3
of rat Na.sub.v2 channel, was combined to hemocyanin, then a white
rabbit was immunized with the hemocyanin-combined peptide as an
immunogen, and anti-rat Na.sub.v2 rabbit antiserum was constructed
by a usual method. The constructed antiserum was purified by a
column in which the peptide used as the immunogen was fixed, and an
anti-Na.sub.v2 antibody was obtained. The specificity of the
anti-Na.sub.v2 antibody was confirmed by Western blot and
immunohistochemical analysis. When the purified anti-Na.sub.v2
antibody was used, no non-specific positive signal was observed in
sections of brain, lung, dorsal root ganglia and tongue prepared
from gene-deficient mice.
[0084] Next, nerve cells in dorsal root ganglia were isolated. The
dorsal root ganglia were prepared from wild-type and Na.sub.v2
gene-deficient mice of 8-16 weeks of age. Nerve cells were
dispersedly isolated from the dorsal root ganglia according to the
method of Renganathan et al. (J Newrophysiol 84, 710-718, 2000).
Before used for an ion imaging experiment, the dispersedly isolated
nerve cells were cultured under the condition of the humidity of
100% and the temperature of 37.degree. C., and with 5% of carbon
dioxide, then adhered to the glass of culture plates. All nerve
cells were confirmed to be Na.sub.v2-positive by staining nerve
cells of dorsal root ganglia derived from wild-type mice with the
above-mentioned anti-Na.sub.v2 antibody. The size of the
dispersedly isolated nerve cells were comprised of 3 groups of
small (25 micron or smaller in diameter: about 50%), medium (25 to
40 micron in diameter: about 40%), and large (40 micron or larger
in diameter: about 10%). However, there was no difference between
the materials isolated from wild-type and gene-deficient mice in
the size, shape and survival rate of these 3 types of cell. The
survival rate was verified by Tripan blue staining.
[0085] In addition, nerve cells of subfornical organs were also
isolated. The subfornical organs were prepared from wild-type and
Na.sub.v2 gene-deficient mice of 8-16 weeks of age. In order to
visualize the subfornical organs, Evans blue was intraperitoneally
injected in advance. The subfornical organs were dispersed
according to the method of Jurzak et al. (Brain Res 662, 198-208,
1994). As in the case of nerve cells of dorsal root ganglia, the
dispersedly isolated nerve cells were cultured under the condition
of the humidity of 100% and the temperature of 37.degree. C., and
with 5% of carbon dioxide, then adhered to the glass of culture
plates, and then used for the experiment. Some nerve cells of
subfornical organs derived from wild-type mice were stained with
the above-mentioned anti-Na.sub.v2 antibody, and a ratio of
Na.sub.v2-positive nerve cells was about 20 to 30%. There was no
difference between the nerve cells isolated from wild-type and
gene-deficient mice in the size and survival rate.
[0086] With regard to the nerve cells of dorsal root ganglia or
subfornical organs prepared from the above-mentioned wild-type and
Na.sub.v2 gene-deficient mice, intracellular sodium ion and
intracellular calcium ion were measured. SBFI/AM (sodium-binding
benzofuran isophthalate acetoxymethyl ester) was used for measuring
intracellular sodium ion, and Fura-2/AM was used for measuring
intracellular calcium ion. Cultured cells loaded with these
indicators were adhered to culture plates, and the culture plates
were fixed to the stage of a microscope. Fluorescence ratio
(F340/F380) was monitored by the fluorescence imaging system. In
order to measure data, samplings were conducted every 10 seconds
for the nerve cells of dorsal root ganglia, and every 20 seconds
for those of subfornical organs respectively. Before the
measurement, the nerve cells were incubated with physiological
isotonic liquid (145 mM of extracellular sodium concentration) for
30 to 60 minutes, and while measuring, the nerve cells were exposed
to a certain perfusate (5 mM of KCl, 2.5 mM of CaCl.sub.2, 1 mM of
MgCl.sub.2, 10 mM of HEPES, 10 mM of NaOH, NaCl at the prescribed
concentration, pH 7.4, (neutralization by HCl), and the perfusate
(extracellular liquid) was perfused at a certain speed (1 ml/min)
at room temperature.
[0087] The results of the fluorescence imaging of fluorescence
ratio (F340/F380) in nerve cells of dorsal root ganglia are shown
in FIG. 9 and FIG. 10. As shown in FIG. 9, when the concentration
of the extracellular NaCl was increased to 145 to 170 mM, the
concentration of intracellular sodium ion in nerve cells of dorsal
root ganglia derived from wild-type mice showed a rapid increase,
and reached to steady state straightly. On the other hand, in the
nerve cells of dorsal root ganglia derived from gene-deficient
mice, an increase of the intracellular sodium ion concentration,
such as observed in wild-type mice, was not observed at all (FIG.
9a and 9b). Further, the increase of sodium in the nerve cells of
dorsal root ganglia derived from wild-type mice was observed in
nerve cells of every size (FIG. 9c). This is consistent with the
fact that Na.sub.v2 expresses in every nerve cells of dorsal root
ganglia of wild-type mice.
[0088] In addition, as shown in FIG. 10, the increase of the
intracellular sodium ion concentration was caused not by osmotic
pressure stimulus using mannitol or by single stimulus of chlorine
ions using choline chloride, but by single stimulus of sodium ions
using sodium methanesulfonate (FIG. 10a). Accordingly, it has been
found that this phenomenon is caused only by the increase of sodium
ion concentration. When the extracellular sodium concentrations
were arranged to be 120, 130, 140, 150, 160, 165, 170, 180, 190 and
200 mM, 10 concentrations in all, with sodium chloride and the
changes in intracellular sodium ion concentration were analyzed,
there was no response in the range of 120 to 150 mM, the increase
was observed in the extracellular sodium ion concentration of 160
and 165 mM, and extremely significant increase was observed in the
extracellular sodium ion concentration of 170 mM and higher (FIG.
10b). In case the extracellular sodium was rearranged to the
original concentration of 145 mM at that time, it was observed that
the intracellular sodium concentration gradually changed to the
original concentration. As there was no intracellular sodium store,
it was concluded that this increase of the intracellular sodium
concentration was attributed to an influx from extracellular
regions via Na.sub.v2 channel. The threshold value of the channel
opening is presumed to be in the range of 160 to 170 mM.
[0089] In order to investigate the possibility that molecules other
than Na.sub.v2 channel are involved in the influx of sodium into
the cells accompanied with this increase of the extracellular
sodium ion concentration, the effects of each blocker of various
sodium ion pumps, sodium ion transporters, sodium ion channels were
examined. As a result, it was found that there was no influence of
TTX-sensitive voltage-dependent sodium channels (FIG. 10c),
amiloride-sensitive sodium channels (FIG. 10c), sodium glucose
co-transporters, sodium calcium antiporters, sodium potassium
chloride transporters and sodium potassium pumps. Further, it was
concluded that TTX-nonsensitive voltage-dependent sodium channels
were not involved in this phenomenon observed in cell types of
every size because they expressed specifically in small nerve cells
of dorsal root ganglia. The fact that sodium calcium antiporters
were not involved in this phenomenon was also confirmed by calcium
imaging (FIG. 10d).
[0090] The results of the fluorescence imaging of fluorescence
ratio (F340/F380) in nerve cells of subfornical organs are shown in
FIG. 11. As shown in FIG. 11, basically same results as in the case
of the nerve cells of dorsal root ganglia are obtained also in the
nerve cells of subfornical organs, which are organs for detecting
sodium ion concentration in the central nervous system. About 20 to
30% of the nerve cells of subfornical organs were Na.sub.v2
immuno-positive cells, and
Sequence CWU 1
1
8 1 446 DNA Rattus norvegicus 1 atgttgactt ccccagagcc gaagggcctt
gtcccattca cggcagagtc acttgaactt 60 ataaaaaatc acattgctaa
aaaatgcaac gaagagcatg aagaagaaga tttaaaacca 120 agccgggata
tagaagcagg caaaaaactt ccatttgcct atggaaccct tcctcaagga 180
accgtgtcag agcccttgga agatgtggat ccatactact atgttaagag aaatactttc
240 atggtcttaa acagaaacag agtcatcttc aggttcaatg cggtttccat
cctctgcacg 300 ttgtctcctt taagctctct cagaagagct gttatcaagg
ttttggtgca cccccttttg 360 cgcctgctga ttttaattag tgttctcacc
gacagcatac ttatgtgcat gagtaaccta 420 ccggaatgga tattggcagt agagaa
446 2 5482 DNA Mus musculus CDS (252)..(5297) 2 cacgcgtcga
ctagtacggg ggggggggag gggttggtct gtaggtggtc tctgggtctg 60
tggagctagc ctggtggctg agtgtttagc tggaagcagc agtggaccgc aaccacattg
120 caacaacctc cgtagtagag atctgagaag acaagcccag gagagcaaag
ggctctcgtg 180 agccttgcat ctggggttct tgctggagtt ttagtgaaga
ctagcatttg acagcaacta 240 taaaaccgaa a atg ttg act tcc cca gag ccg
aag ggc ctt gtc cca ttt 290 Met Leu Thr Ser Pro Glu Pro Lys Gly Leu
Val Pro Phe 1 5 10 aca aca gag tca ctt gaa ctt ata gaa aat cac att
gct aaa aaa tgc 338 Thr Thr Glu Ser Leu Glu Leu Ile Glu Asn His Ile
Ala Lys Lys Cys 15 20 25 aat gaa gac ccc gaa gaa gaa gaa ggt tta
aaa cca agt cgt aat cta 386 Asn Glu Asp Pro Glu Glu Glu Glu Gly Leu
Lys Pro Ser Arg Asn Leu 30 35 40 45 gaa gct ggc aaa aga ctt cca att
ccc tat gga acc ctc cct cga gga 434 Glu Ala Gly Lys Arg Leu Pro Ile
Pro Tyr Gly Thr Leu Pro Arg Gly 50 55 60 acc gtg tca gag ccc ttg
gaa gat gtg gat cca tac tac tat gtt aag 482 Thr Val Ser Glu Pro Leu
Glu Asp Val Asp Pro Tyr Tyr Tyr Val Lys 65 70 75 aga aat act ttc
atg gtc tta aac aga agc aga gtc atc ttc agg ttc 530 Arg Asn Thr Phe
Met Val Leu Asn Arg Ser Arg Val Ile Phe Arg Phe 80 85 90 aat gcg
gtt tcc atc ttc tgc aca ttg tct cct cta aac tcc ctc aga 578 Asn Ala
Val Ser Ile Phe Cys Thr Leu Ser Pro Leu Asn Ser Leu Arg 95 100 105
aga gca gct atc aag gct ttg gtg cat ccc ctt ttt cgc ctg ctg att 626
Arg Ala Ala Ile Lys Ala Leu Val His Pro Leu Phe Arg Leu Leu Ile 110
115 120 125 tta atc agc gtt ctc act gac agc ata ctt atg tgc atg agt
aat cta 674 Leu Ile Ser Val Leu Thr Asp Ser Ile Leu Met Cys Met Ser
Asn Leu 130 135 140 cca gaa tgg ata ttg gca ata gag aat act ttg ctt
ggg att tac gca 722 Pro Glu Trp Ile Leu Ala Ile Glu Asn Thr Leu Leu
Gly Ile Tyr Ala 145 150 155 ttt gaa ata ctt gta aaa gtc att gca aga
ggt atc tgg gca ggt tca 770 Phe Glu Ile Leu Val Lys Val Ile Ala Arg
Gly Ile Trp Ala Gly Ser 160 165 170 ttt tcc ttc ctt ggg gat ctt tgg
aac tgg ctt gat ttc agt gta act 818 Phe Ser Phe Leu Gly Asp Leu Trp
Asn Trp Leu Asp Phe Ser Val Thr 175 180 185 ttg ttc gag cta atc aca
agg ttt tca cct cta agc tcc ttt tta atg 866 Leu Phe Glu Leu Ile Thr
Arg Phe Ser Pro Leu Ser Ser Phe Leu Met 190 195 200 205 ctt aaa act
atc aga act ttc cga att ttg aag att atc cct ttg aac 914 Leu Lys Thr
Ile Arg Thr Phe Arg Ile Leu Lys Ile Ile Pro Leu Asn 210 215 220 cac
ggc ctg cag tct att gtg atg aca ctg gcc cag tgt ttg aag aaa 962 His
Gly Leu Gln Ser Ile Val Met Thr Leu Ala Gln Cys Leu Lys Lys 225 230
235 cta ttt ggt gcc att gcc cta gct ctg ttt ttt ctg gct gtg ttt tca
1010 Leu Phe Gly Ala Ile Ala Leu Ala Leu Phe Phe Leu Ala Val Phe
Ser 240 245 250 cta ctt gga atg ggc ctc ttc atg ggc aac ctg aag cac
aaa tgt ctg 1058 Leu Leu Gly Met Gly Leu Phe Met Gly Asn Leu Lys
His Lys Cys Leu 255 260 265 cgg tgg cca gaa gaa aat gaa aat gaa acg
ctg cac aac aga act gga 1106 Arg Trp Pro Glu Glu Asn Glu Asn Glu
Thr Leu His Asn Arg Thr Gly 270 275 280 285 agc ctt aac tat agt cca
gaa aga ata aac ttc tac tac atg gaa gga 1154 Ser Leu Asn Tyr Ser
Pro Glu Arg Ile Asn Phe Tyr Tyr Met Glu Gly 290 295 300 gcg aaa tat
gct ctc ctt tgc ggc aac agg aca gat gct ggc cag tgt 1202 Ala Lys
Tyr Ala Leu Leu Cys Gly Asn Arg Thr Asp Ala Gly Gln Cys 305 310 315
ccg gaa ggt tat gtg tgt gta aaa gaa ggc aca aat cct gac aat ggc
1250 Pro Glu Gly Tyr Val Cys Val Lys Glu Gly Thr Asn Pro Asp Asn
Gly 320 325 330 ttc aca agt ttt gac aac ttt ggc tgg tcc ctt ctt gct
atg ttt cga 1298 Phe Thr Ser Phe Asp Asn Phe Gly Trp Ser Leu Leu
Ala Met Phe Arg 335 340 345 ttg atg aca cag gat tac cct gaa tta ctt
tat cac cag atc ctt tat 1346 Leu Met Thr Gln Asp Tyr Pro Glu Leu
Leu Tyr His Gln Ile Leu Tyr 350 355 360 365 gct tca gga aag gtc tac
atg ata ttt ttt gtt atg atc agt ttc tgg 1394 Ala Ser Gly Lys Val
Tyr Met Ile Phe Phe Val Met Ile Ser Phe Trp 370 375 380 ttt gcc ttc
tat ttg aca agt ttg ttc ttg ggc ata ctc act atg acc 1442 Phe Ala
Phe Tyr Leu Thr Ser Leu Phe Leu Gly Ile Leu Thr Met Thr 385 390 395
tat gaa aag gaa aag cag aga gcc tgt gag gaa tct gga ggc ctt gat
1490 Tyr Glu Lys Glu Lys Gln Arg Ala Cys Glu Glu Ser Gly Gly Leu
Asp 400 405 410 ccc aaa tgt caa cag aca gtg aaa gaa ctc gac gaa gaa
aat gac gca 1538 Pro Lys Cys Gln Gln Thr Val Lys Glu Leu Asp Glu
Glu Asn Asp Ala 415 420 425 gct gag atg gaa act aca caa ata gaa atg
aag aaa aga tcc cca act 1586 Ala Glu Met Glu Thr Thr Gln Ile Glu
Met Lys Lys Arg Ser Pro Thr 430 435 440 445 tct ata aac acc aca ctg
gat ata ctg gaa gac act acc ctc gga cac 1634 Ser Ile Asn Thr Thr
Leu Asp Ile Leu Glu Asp Thr Thr Leu Gly His 450 455 460 aga gaa gaa
cca gaa aca tcc agg aag aaa tgc cca ata tgt tgg cat 1682 Arg Glu
Glu Pro Glu Thr Ser Arg Lys Lys Cys Pro Ile Cys Trp His 465 470 475
aag ttt att aaa acc tgc ttc atc tgg aaa tgc tct ccc tgt tgg gta
1730 Lys Phe Ile Lys Thr Cys Phe Ile Trp Lys Cys Ser Pro Cys Trp
Val 480 485 490 aaa ctg aac gag ttt gct gat aga gtt ata aca cac cca
ttg gct gat 1778 Lys Leu Asn Glu Phe Ala Asp Arg Val Ile Thr His
Pro Leu Ala Asp 495 500 505 ctt ttt ctt gtc atc tgc atc gtt tta aac
ata tgc ttc ctc gcc cta 1826 Leu Phe Leu Val Ile Cys Ile Val Leu
Asn Ile Cys Phe Leu Ala Leu 510 515 520 525 gaa cat ttt cca atg agc
gag gag ctc agg tct ctc ctt cac gtt gga 1874 Glu His Phe Pro Met
Ser Glu Glu Leu Arg Ser Leu Leu His Val Gly 530 535 540 aat ttg gtt
ttt att gga att tac aca ata gaa ctg att ttg aag ata 1922 Asn Leu
Val Phe Ile Gly Ile Tyr Thr Ile Glu Leu Ile Leu Lys Ile 545 550 555
atc gct atg cat cca tat ggg tat ttt caa ata agc tgg aat att ttt
1970 Ile Ala Met His Pro Tyr Gly Tyr Phe Gln Ile Ser Trp Asn Ile
Phe 560 565 570 gac agt ata ctt gtg gtt ttg gag tta aca gaa att tta
cta gca gat 2018 Asp Ser Ile Leu Val Val Leu Glu Leu Thr Glu Ile
Leu Leu Ala Asp 575 580 585 gtt gaa gga cta gct gtt tta ata aca gtc
cca ttg ata ttt ata aaa 2066 Val Glu Gly Leu Ala Val Leu Ile Thr
Val Pro Leu Ile Phe Ile Lys 590 595 600 605 ctg ggg aag tac gga cca
cca ttt aag agt ttg atg cgc atc ctt ggt 2114 Leu Gly Lys Tyr Gly
Pro Pro Phe Lys Ser Leu Met Arg Ile Leu Gly 610 615 620 agc tca ttg
atg gcc ctg aaa gat ttg gtc ctg ttg ctc tgc ata ttc 2162 Ser Ser
Leu Met Ala Leu Lys Asp Leu Val Leu Leu Leu Cys Ile Phe 625 630 635
gtt tac ttc tct gct gtg ttc ggc atg aag ctg ttt ggt cga agt tac
2210 Val Tyr Phe Ser Ala Val Phe Gly Met Lys Leu Phe Gly Arg Ser
Tyr 640 645 650 aag gat tgt gtc tgc cac ata aag gaa gac tgc caa ccc
caa cgc tgg 2258 Lys Asp Cys Val Cys His Ile Lys Glu Asp Cys Gln
Pro Gln Arg Trp 655 660 665 cac atg agt gac ttc ctt cat gcc tac atg
acc gtg ttc cga atc ctc 2306 His Met Ser Asp Phe Leu His Ala Tyr
Met Thr Val Phe Arg Ile Leu 670 675 680 685 tgt gga gag tgg ata gag
aca tta tgg gag tgt atg gag gtt gca ggc 2354 Cys Gly Glu Trp Ile
Glu Thr Leu Trp Glu Cys Met Glu Val Ala Gly 690 695 700 cag gcc tgg
tgt att cct ttt tac atg atg gtc att tta att gga aac 2402 Gln Ala
Trp Cys Ile Pro Phe Tyr Met Met Val Ile Leu Ile Gly Asn 705 710 715
tta ttg ata ctt tac ctc ttt gtg aca ttg gtg agc tct ttc agt tac
2450 Leu Leu Ile Leu Tyr Leu Phe Val Thr Leu Val Ser Ser Phe Ser
Tyr 720 725 730 tat gat gct aca tcg gaa gtg aac aaa gaa gcc aaa aac
ctt cag ctt 2498 Tyr Asp Ala Thr Ser Glu Val Asn Lys Glu Ala Lys
Asn Leu Gln Leu 735 740 745 gcc atg gca agg ata aag tcg gga ata aac
tcc atg ctt ctt aaa tta 2546 Ala Met Ala Arg Ile Lys Ser Gly Ile
Asn Ser Met Leu Leu Lys Leu 750 755 760 765 atg tgc aca gaa aga agt
gtt cct aca gaa gca aca gac caa ata tgt 2594 Met Cys Thr Glu Arg
Ser Val Pro Thr Glu Ala Thr Asp Gln Ile Cys 770 775 780 gat cca agt
gtt aaa gag aat att tct ggc cat act ctt tct gaa ctg 2642 Asp Pro
Ser Val Lys Glu Asn Ile Ser Gly His Thr Leu Ser Glu Leu 785 790 795
agc aac acc caa act ttc ctc aga tat aag gac cag agc agc agc act
2690 Ser Asn Thr Gln Thr Phe Leu Arg Tyr Lys Asp Gln Ser Ser Ser
Thr 800 805 810 gag aaa act cca gtg act gaa tct gag agt caa tct ctg
att gct agt 2738 Glu Lys Thr Pro Val Thr Glu Ser Glu Ser Gln Ser
Leu Ile Ala Ser 815 820 825 ccc agt gcc tct gaa act gtg ccg att gct
tca gga gaa tct gat ata 2786 Pro Ser Ala Ser Glu Thr Val Pro Ile
Ala Ser Gly Glu Ser Asp Ile 830 835 840 845 gaa aat ctg gat aac aag
gag act cgg agc aag tct ggg aat gga ggc 2834 Glu Asn Leu Asp Asn
Lys Glu Thr Arg Ser Lys Ser Gly Asn Gly Gly 850 855 860 agt aaa gag
aaa atg aag cag tct agc tca tct gag tgc agc aca gtt 2882 Ser Lys
Glu Lys Met Lys Gln Ser Ser Ser Ser Glu Cys Ser Thr Val 865 870 875
gat atc gct att tct gaa gaa gaa gaa atg gtc tat gaa cat gaa aag
2930 Asp Ile Ala Ile Ser Glu Glu Glu Glu Met Val Tyr Glu His Glu
Lys 880 885 890 tca aag ctt cat aaa aat ggt tat gaa cgc aaa tct tca
act ggt caa 2978 Ser Lys Leu His Lys Asn Gly Tyr Glu Arg Lys Ser
Ser Thr Gly Gln 895 900 905 atc agt aga gaa tct agg aat gga aag att
tgg aaa aac atc agg aaa 3026 Ile Ser Arg Glu Ser Arg Asn Gly Lys
Ile Trp Lys Asn Ile Arg Lys 910 915 920 925 act tgc tgc aag ata gta
gag aac agc tgg ttt gag tgt ttc att ggc 3074 Thr Cys Cys Lys Ile
Val Glu Asn Ser Trp Phe Glu Cys Phe Ile Gly 930 935 940 ctg gtc act
ctg ctc tgc aca ggc act ctg gct ctt gaa gac ata tat 3122 Leu Val
Thr Leu Leu Cys Thr Gly Thr Leu Ala Leu Glu Asp Ile Tyr 945 950 955
att gat cag aga aaa acc act aaa atc tta ctg gaa tat gcg gac atg
3170 Ile Asp Gln Arg Lys Thr Thr Lys Ile Leu Leu Glu Tyr Ala Asp
Met 960 965 970 ata ttt gca tac atc ttc att ctg gag atg ctt ctc aag
tgg gtg gct 3218 Ile Phe Ala Tyr Ile Phe Ile Leu Glu Met Leu Leu
Lys Trp Val Ala 975 980 985 tat ggc ttt aaa gcc ttt ttc tcc aac aac
tgg tac aaa ctg gac ttt 3266 Tyr Gly Phe Lys Ala Phe Phe Ser Asn
Asn Trp Tyr Lys Leu Asp Phe 990 995 1000 1005 atg gtt gtt atc gtg
ttt tgt ctt agc tta ata ggc aaa act cga gaa 3314 Met Val Val Ile
Val Phe Cys Leu Ser Leu Ile Gly Lys Thr Arg Glu 1010 1015 1020 gat
ctg aac cct ctg aca tca ata aag ttc ctt cga gca cta aga gtt 3362
Asp Leu Asn Pro Leu Thr Ser Ile Lys Phe Leu Arg Ala Leu Arg Val
1025 1030 1035 ctg tcg cag ttt gaa aga atg aag gtg gtc ctg aga gct
ttg ata aaa 3410 Leu Ser Gln Phe Glu Arg Met Lys Val Val Leu Arg
Ala Leu Ile Lys 1040 1045 1050 aca acc tta ccc act gtg agc gtg ttt
cta gtc tgc cta atg atc tgg 3458 Thr Thr Leu Pro Thr Val Ser Val
Phe Leu Val Cys Leu Met Ile Trp 1055 1060 1065 ctg ctt ttc agt gtt
att gga gtg cag tta ttt gct ggc aag ttc tat 3506 Leu Leu Phe Ser
Val Ile Gly Val Gln Leu Phe Ala Gly Lys Phe Tyr 1070 1075 1080 1085
gaa tgc att gac cca aca aag gga gaa aga ttc cct gta ttt gaa gtt
3554 Glu Cys Ile Asp Pro Thr Lys Gly Glu Arg Phe Pro Val Phe Glu
Val 1090 1095 1100 atg aat aaa agt cag tgt gaa aaa ctg tta ttc aat
gaa tca atg ccg 3602 Met Asn Lys Ser Gln Cys Glu Lys Leu Leu Phe
Asn Glu Ser Met Pro 1105 1110 1115 tgg gag aat gca aaa ctg aac ttt
gat aat gtt gga aat ggt ttt ctt 3650 Trp Glu Asn Ala Lys Leu Asn
Phe Asp Asn Val Gly Asn Gly Phe Leu 1120 1125 1130 tct tta ctc caa
gtg gca aca ttt aat gga tgg atc agt att atg aat 3698 Ser Leu Leu
Gln Val Ala Thr Phe Asn Gly Trp Ile Ser Ile Met Asn 1135 1140 1145
tca gca att gat tct gtt ggt gta aac atg cag ccc agc ttt gag tac
3746 Ser Ala Ile Asp Ser Val Gly Val Asn Met Gln Pro Ser Phe Glu
Tyr 1150 1155 1160 1165 aac ctc tac atg tat agt tac ttt atc atc ttt
gtt atc ttt gga tta 3794 Asn Leu Tyr Met Tyr Ser Tyr Phe Ile Ile
Phe Val Ile Phe Gly Leu 1170 1175 1180 ttt ctt cct ctc tgt atg ctg
att ggt gtt att att cgc aat ttc aac 3842 Phe Leu Pro Leu Cys Met
Leu Ile Gly Val Ile Ile Arg Asn Phe Asn 1185 1190 1195 aag cag aaa
att aag cag gga gga tca aac atc ttt ata aca gta aaa 3890 Lys Gln
Lys Ile Lys Gln Gly Gly Ser Asn Ile Phe Ile Thr Val Lys 1200 1205
1210 cag aaa aaa cag tac cgg gcc ctg aag aag ctc ttg tat gca gac
gtc 3938 Gln Lys Lys Gln Tyr Arg Ala Leu Lys Lys Leu Leu Tyr Ala
Asp Val 1215 1220 1225 cag aaa cca aca ccc cgc ccc aga aac aaa ttc
caa ggc ttc ctt ttt 3986 Gln Lys Pro Thr Pro Arg Pro Arg Asn Lys
Phe Gln Gly Phe Leu Phe 1230 1235 1240 1245 gac cta gta aca cac cgt
gtc ttt aat gtt atc atc ata ctt ctt atc 4034 Asp Leu Val Thr His
Arg Val Phe Asn Val Ile Ile Ile Leu Leu Ile 1250 1255 1260 tgt ttc
caa gca aca acc att atg ata caa aag gat gag cag agt cca 4082 Cys
Phe Gln Ala Thr Thr Ile Met Ile Gln Lys Asp Glu Gln Ser Pro 1265
1270 1275 caa atg gaa act gcc atc ttc tgg atg aac tcc att ttt gtc
atg ctg 4130 Gln Met Glu Thr Ala Ile Phe Trp Met Asn Ser Ile Phe
Val Met Leu 1280 1285 1290 ttc act ctg gaa tgc ata ctg aag ctc act
gcc ttc cgt tgc cac tac 4178 Phe Thr Leu Glu Cys Ile Leu Lys Leu
Thr Ala Phe Arg Cys His Tyr 1295 1300 1305 ttc acc agt gca tgg aat
gtt cat gac ttt atg gtg gtc att ttc tcc 4226 Phe Thr Ser Ala Trp
Asn Val His Asp Phe Met Val Val Ile Phe Ser 1310 1315 1320 1325 att
aca ggg ctg ctg cta ccc ttg aca ata gga caa tac ttt gtg cct 4274
Ile Thr Gly Leu Leu Leu Pro Leu Thr Ile Gly Gln Tyr Phe Val Pro
1330 1335 1340 cct tcc ctg gtg cag ctg att ctt ctc tct cga gtc atc
cac atc ctg 4322 Pro Ser Leu Val Gln Leu Ile Leu Leu Ser Arg Val
Ile His Ile Leu 1345 1350 1355 cgt cct ggg aaa gga ccg aag gtg ttc
cat gac ctg atg ctt ccc ttg 4370 Arg Pro Gly Lys Gly Pro Lys Val
Phe His Asp Leu Met Leu Pro Leu 1360 1365 1370 att ctg gcg ctc cca
gca ttg ctg aac att agt ctt ctc atc ttc ctg 4418 Ile Leu Ala Leu
Pro Ala Leu Leu Asn Ile Ser Leu Leu Ile Phe Leu 1375 1380 1385 gtc
atg ttc atc tac gcc atc ttt gga atg tac aac ttt gcc tat gta 4466
Val Met Phe Ile Tyr Ala Ile Phe Gly Met Tyr Asn Phe Ala Tyr Val
1390 1395 1400 1405 aag aaa gaa gcc gga att aat gat gtg tcc aac ttt
gag acc ttt gga 4514 Lys Lys Glu Ala Gly Ile Asn Asp Val Ser Asn
Phe Glu Thr Phe Gly 1410 1415 1420 agc agt atg ctc tgt ctc ttc caa
gtt aca acg ttt tct ggt tgg gac 4562 Ser Ser Met Leu Cys Leu Phe
Gln Val Thr Thr Phe Ser Gly Trp Asp 1425 1430 1435 ggg atg ctg
gat
gca att ttc aac agt cag tgg tct gac tgc gat cct 4610 Gly Met Leu
Asp Ala Ile Phe Asn Ser Gln Trp Ser Asp Cys Asp Pro 1440 1445 1450
gat aaa att aat cca ggg act cag gtc aag gga gat tgt ggg agc cct
4658 Asp Lys Ile Asn Pro Gly Thr Gln Val Lys Gly Asp Cys Gly Ser
Pro 1455 1460 1465 tct gtt ggg att tct tat ttt gtc agt tac atc ctc
ata tca tgg ttg 4706 Ser Val Gly Ile Ser Tyr Phe Val Ser Tyr Ile
Leu Ile Ser Trp Leu 1470 1475 1480 1485 atc att gtt aac atg tac att
gtg ttg atc atg gag ttc tta agt att 4754 Ile Ile Val Asn Met Tyr
Ile Val Leu Ile Met Glu Phe Leu Ser Ile 1490 1495 1500 cct tct cag
aaa aaa agc agg acc ttg agt gaa gat gac ttt agg aga 4802 Pro Ser
Gln Lys Lys Ser Arg Thr Leu Ser Glu Asp Asp Phe Arg Arg 1505 1510
1515 ttc ttc cgg gtg tgg aac agg ttt gac cct gat agg acc cag tac
ata 4850 Phe Phe Arg Val Trp Asn Arg Phe Asp Pro Asp Arg Thr Gln
Tyr Ile 1520 1525 1530 gac tct agc aag ctt tct gat ttt gca gct gct
ctg gat cct cct ctt 4898 Asp Ser Ser Lys Leu Ser Asp Phe Ala Ala
Ala Leu Asp Pro Pro Leu 1535 1540 1545 ttc atg gca aaa cca aac aag
ggc cag ctt gtg gcc atg gat ctc ccc 4946 Phe Met Ala Lys Pro Asn
Lys Gly Gln Leu Val Ala Met Asp Leu Pro 1550 1555 1560 1565 atg gct
gcg gga gac aga atc cac tgc ctc gac att tta ctt gcc ttt 4994 Met
Ala Ala Gly Asp Arg Ile His Cys Leu Asp Ile Leu Leu Ala Phe 1570
1575 1580 acg aaa aga gtg atg gga aag gat gag agg gtg gag aaa atc
ctt tca 5042 Thr Lys Arg Val Met Gly Lys Asp Glu Arg Val Glu Lys
Ile Leu Ser 1585 1590 1595 gag ata gaa tcc ggg ttc atg tta gcg aac
cct ttc aaa atc act tat 5090 Glu Ile Glu Ser Gly Phe Met Leu Ala
Asn Pro Phe Lys Ile Thr Tyr 1600 1605 1610 gag ccg att aca act act
ttg aaa cgc aaa caa gag gca gtt tca gca 5138 Glu Pro Ile Thr Thr
Thr Leu Lys Arg Lys Gln Glu Ala Val Ser Ala 1615 1620 1625 acc atc
atc cag cgt gca tat aaa agc tac cgc tta agg caa aat gac 5186 Thr
Ile Ile Gln Arg Ala Tyr Lys Ser Tyr Arg Leu Arg Gln Asn Asp 1630
1635 1640 1645 aag aat gta tca gat act cct gct ata gat gac cgc aga
gat gat ctt 5234 Lys Asn Val Ser Asp Thr Pro Ala Ile Asp Asp Arg
Arg Asp Asp Leu 1650 1655 1660 act tct aaa ggt gct cac tct ggc aaa
atc gag gag aag gca tct att 5282 Thr Ser Lys Gly Ala His Ser Gly
Lys Ile Glu Glu Lys Ala Ser Ile 1665 1670 1675 cag acc cag att taa
tgacacttcc cacttctact ttctttacat atgtccccaa 5337 Gln Thr Gln Ile
1680 gcactaaatg ttaactgatc ttaagctgga gatcagaaac tagagataat
gataacatct 5397 gtgtgcccag acatctccat gacaagctca gctttagggt
cagtcttctg atgcatcaga 5457 aagacagcag ctcagcgttg ctgcg 5482 3 1681
PRT Mus musculus 3 Met Leu Thr Ser Pro Glu Pro Lys Gly Leu Val Pro
Phe Thr Thr Glu 1 5 10 15 Ser Leu Glu Leu Ile Glu Asn His Ile Ala
Lys Lys Cys Asn Glu Asp 20 25 30 Pro Glu Glu Glu Glu Gly Leu Lys
Pro Ser Arg Asn Leu Glu Ala Gly 35 40 45 Lys Arg Leu Pro Ile Pro
Tyr Gly Thr Leu Pro Arg Gly Thr Val Ser 50 55 60 Glu Pro Leu Glu
Asp Val Asp Pro Tyr Tyr Tyr Val Lys Arg Asn Thr 65 70 75 80 Phe Met
Val Leu Asn Arg Ser Arg Val Ile Phe Arg Phe Asn Ala Val 85 90 95
Ser Ile Phe Cys Thr Leu Ser Pro Leu Asn Ser Leu Arg Arg Ala Ala 100
105 110 Ile Lys Ala Leu Val His Pro Leu Phe Arg Leu Leu Ile Leu Ile
Ser 115 120 125 Val Leu Thr Asp Ser Ile Leu Met Cys Met Ser Asn Leu
Pro Glu Trp 130 135 140 Ile Leu Ala Ile Glu Asn Thr Leu Leu Gly Ile
Tyr Ala Phe Glu Ile 145 150 155 160 Leu Val Lys Val Ile Ala Arg Gly
Ile Trp Ala Gly Ser Phe Ser Phe 165 170 175 Leu Gly Asp Leu Trp Asn
Trp Leu Asp Phe Ser Val Thr Leu Phe Glu 180 185 190 Leu Ile Thr Arg
Phe Ser Pro Leu Ser Ser Phe Leu Met Leu Lys Thr 195 200 205 Ile Arg
Thr Phe Arg Ile Leu Lys Ile Ile Pro Leu Asn His Gly Leu 210 215 220
Gln Ser Ile Val Met Thr Leu Ala Gln Cys Leu Lys Lys Leu Phe Gly 225
230 235 240 Ala Ile Ala Leu Ala Leu Phe Phe Leu Ala Val Phe Ser Leu
Leu Gly 245 250 255 Met Gly Leu Phe Met Gly Asn Leu Lys His Lys Cys
Leu Arg Trp Pro 260 265 270 Glu Glu Asn Glu Asn Glu Thr Leu His Asn
Arg Thr Gly Ser Leu Asn 275 280 285 Tyr Ser Pro Glu Arg Ile Asn Phe
Tyr Tyr Met Glu Gly Ala Lys Tyr 290 295 300 Ala Leu Leu Cys Gly Asn
Arg Thr Asp Ala Gly Gln Cys Pro Glu Gly 305 310 315 320 Tyr Val Cys
Val Lys Glu Gly Thr Asn Pro Asp Asn Gly Phe Thr Ser 325 330 335 Phe
Asp Asn Phe Gly Trp Ser Leu Leu Ala Met Phe Arg Leu Met Thr 340 345
350 Gln Asp Tyr Pro Glu Leu Leu Tyr His Gln Ile Leu Tyr Ala Ser Gly
355 360 365 Lys Val Tyr Met Ile Phe Phe Val Met Ile Ser Phe Trp Phe
Ala Phe 370 375 380 Tyr Leu Thr Ser Leu Phe Leu Gly Ile Leu Thr Met
Thr Tyr Glu Lys 385 390 395 400 Glu Lys Gln Arg Ala Cys Glu Glu Ser
Gly Gly Leu Asp Pro Lys Cys 405 410 415 Gln Gln Thr Val Lys Glu Leu
Asp Glu Glu Asn Asp Ala Ala Glu Met 420 425 430 Glu Thr Thr Gln Ile
Glu Met Lys Lys Arg Ser Pro Thr Ser Ile Asn 435 440 445 Thr Thr Leu
Asp Ile Leu Glu Asp Thr Thr Leu Gly His Arg Glu Glu 450 455 460 Pro
Glu Thr Ser Arg Lys Lys Cys Pro Ile Cys Trp His Lys Phe Ile 465 470
475 480 Lys Thr Cys Phe Ile Trp Lys Cys Ser Pro Cys Trp Val Lys Leu
Asn 485 490 495 Glu Phe Ala Asp Arg Val Ile Thr His Pro Leu Ala Asp
Leu Phe Leu 500 505 510 Val Ile Cys Ile Val Leu Asn Ile Cys Phe Leu
Ala Leu Glu His Phe 515 520 525 Pro Met Ser Glu Glu Leu Arg Ser Leu
Leu His Val Gly Asn Leu Val 530 535 540 Phe Ile Gly Ile Tyr Thr Ile
Glu Leu Ile Leu Lys Ile Ile Ala Met 545 550 555 560 His Pro Tyr Gly
Tyr Phe Gln Ile Ser Trp Asn Ile Phe Asp Ser Ile 565 570 575 Leu Val
Val Leu Glu Leu Thr Glu Ile Leu Leu Ala Asp Val Glu Gly 580 585 590
Leu Ala Val Leu Ile Thr Val Pro Leu Ile Phe Ile Lys Leu Gly Lys 595
600 605 Tyr Gly Pro Pro Phe Lys Ser Leu Met Arg Ile Leu Gly Ser Ser
Leu 610 615 620 Met Ala Leu Lys Asp Leu Val Leu Leu Leu Cys Ile Phe
Val Tyr Phe 625 630 635 640 Ser Ala Val Phe Gly Met Lys Leu Phe Gly
Arg Ser Tyr Lys Asp Cys 645 650 655 Val Cys His Ile Lys Glu Asp Cys
Gln Pro Gln Arg Trp His Met Ser 660 665 670 Asp Phe Leu His Ala Tyr
Met Thr Val Phe Arg Ile Leu Cys Gly Glu 675 680 685 Trp Ile Glu Thr
Leu Trp Glu Cys Met Glu Val Ala Gly Gln Ala Trp 690 695 700 Cys Ile
Pro Phe Tyr Met Met Val Ile Leu Ile Gly Asn Leu Leu Ile 705 710 715
720 Leu Tyr Leu Phe Val Thr Leu Val Ser Ser Phe Ser Tyr Tyr Asp Ala
725 730 735 Thr Ser Glu Val Asn Lys Glu Ala Lys Asn Leu Gln Leu Ala
Met Ala 740 745 750 Arg Ile Lys Ser Gly Ile Asn Ser Met Leu Leu Lys
Leu Met Cys Thr 755 760 765 Glu Arg Ser Val Pro Thr Glu Ala Thr Asp
Gln Ile Cys Asp Pro Ser 770 775 780 Val Lys Glu Asn Ile Ser Gly His
Thr Leu Ser Glu Leu Ser Asn Thr 785 790 795 800 Gln Thr Phe Leu Arg
Tyr Lys Asp Gln Ser Ser Ser Thr Glu Lys Thr 805 810 815 Pro Val Thr
Glu Ser Glu Ser Gln Ser Leu Ile Ala Ser Pro Ser Ala 820 825 830 Ser
Glu Thr Val Pro Ile Ala Ser Gly Glu Ser Asp Ile Glu Asn Leu 835 840
845 Asp Asn Lys Glu Thr Arg Ser Lys Ser Gly Asn Gly Gly Ser Lys Glu
850 855 860 Lys Met Lys Gln Ser Ser Ser Ser Glu Cys Ser Thr Val Asp
Ile Ala 865 870 875 880 Ile Ser Glu Glu Glu Glu Met Val Tyr Glu His
Glu Lys Ser Lys Leu 885 890 895 His Lys Asn Gly Tyr Glu Arg Lys Ser
Ser Thr Gly Gln Ile Ser Arg 900 905 910 Glu Ser Arg Asn Gly Lys Ile
Trp Lys Asn Ile Arg Lys Thr Cys Cys 915 920 925 Lys Ile Val Glu Asn
Ser Trp Phe Glu Cys Phe Ile Gly Leu Val Thr 930 935 940 Leu Leu Cys
Thr Gly Thr Leu Ala Leu Glu Asp Ile Tyr Ile Asp Gln 945 950 955 960
Arg Lys Thr Thr Lys Ile Leu Leu Glu Tyr Ala Asp Met Ile Phe Ala 965
970 975 Tyr Ile Phe Ile Leu Glu Met Leu Leu Lys Trp Val Ala Tyr Gly
Phe 980 985 990 Lys Ala Phe Phe Ser Asn Asn Trp Tyr Lys Leu Asp Phe
Met Val Val 995 1000 1005 Ile Val Phe Cys Leu Ser Leu Ile Gly Lys
Thr Arg Glu Asp Leu Asn 1010 1015 1020 Pro Leu Thr Ser Ile Lys Phe
Leu Arg Ala Leu Arg Val Leu Ser Gln 1025 1030 1035 1040 Phe Glu Arg
Met Lys Val Val Leu Arg Ala Leu Ile Lys Thr Thr Leu 1045 1050 1055
Pro Thr Val Ser Val Phe Leu Val Cys Leu Met Ile Trp Leu Leu Phe
1060 1065 1070 Ser Val Ile Gly Val Gln Leu Phe Ala Gly Lys Phe Tyr
Glu Cys Ile 1075 1080 1085 Asp Pro Thr Lys Gly Glu Arg Phe Pro Val
Phe Glu Val Met Asn Lys 1090 1095 1100 Ser Gln Cys Glu Lys Leu Leu
Phe Asn Glu Ser Met Pro Trp Glu Asn 1105 1110 1115 1120 Ala Lys Leu
Asn Phe Asp Asn Val Gly Asn Gly Phe Leu Ser Leu Leu 1125 1130 1135
Gln Val Ala Thr Phe Asn Gly Trp Ile Ser Ile Met Asn Ser Ala Ile
1140 1145 1150 Asp Ser Val Gly Val Asn Met Gln Pro Ser Phe Glu Tyr
Asn Leu Tyr 1155 1160 1165 Met Tyr Ser Tyr Phe Ile Ile Phe Val Ile
Phe Gly Leu Phe Leu Pro 1170 1175 1180 Leu Cys Met Leu Ile Gly Val
Ile Ile Arg Asn Phe Asn Lys Gln Lys 1185 1190 1195 1200 Ile Lys Gln
Gly Gly Ser Asn Ile Phe Ile Thr Val Lys Gln Lys Lys 1205 1210 1215
Gln Tyr Arg Ala Leu Lys Lys Leu Leu Tyr Ala Asp Val Gln Lys Pro
1220 1225 1230 Thr Pro Arg Pro Arg Asn Lys Phe Gln Gly Phe Leu Phe
Asp Leu Val 1235 1240 1245 Thr His Arg Val Phe Asn Val Ile Ile Ile
Leu Leu Ile Cys Phe Gln 1250 1255 1260 Ala Thr Thr Ile Met Ile Gln
Lys Asp Glu Gln Ser Pro Gln Met Glu 1265 1270 1275 1280 Thr Ala Ile
Phe Trp Met Asn Ser Ile Phe Val Met Leu Phe Thr Leu 1285 1290 1295
Glu Cys Ile Leu Lys Leu Thr Ala Phe Arg Cys His Tyr Phe Thr Ser
1300 1305 1310 Ala Trp Asn Val His Asp Phe Met Val Val Ile Phe Ser
Ile Thr Gly 1315 1320 1325 Leu Leu Leu Pro Leu Thr Ile Gly Gln Tyr
Phe Val Pro Pro Ser Leu 1330 1335 1340 Val Gln Leu Ile Leu Leu Ser
Arg Val Ile His Ile Leu Arg Pro Gly 1345 1350 1355 1360 Lys Gly Pro
Lys Val Phe His Asp Leu Met Leu Pro Leu Ile Leu Ala 1365 1370 1375
Leu Pro Ala Leu Leu Asn Ile Ser Leu Leu Ile Phe Leu Val Met Phe
1380 1385 1390 Ile Tyr Ala Ile Phe Gly Met Tyr Asn Phe Ala Tyr Val
Lys Lys Glu 1395 1400 1405 Ala Gly Ile Asn Asp Val Ser Asn Phe Glu
Thr Phe Gly Ser Ser Met 1410 1415 1420 Leu Cys Leu Phe Gln Val Thr
Thr Phe Ser Gly Trp Asp Gly Met Leu 1425 1430 1435 1440 Asp Ala Ile
Phe Asn Ser Gln Trp Ser Asp Cys Asp Pro Asp Lys Ile 1445 1450 1455
Asn Pro Gly Thr Gln Val Lys Gly Asp Cys Gly Ser Pro Ser Val Gly
1460 1465 1470 Ile Ser Tyr Phe Val Ser Tyr Ile Leu Ile Ser Trp Leu
Ile Ile Val 1475 1480 1485 Asn Met Tyr Ile Val Leu Ile Met Glu Phe
Leu Ser Ile Pro Ser Gln 1490 1495 1500 Lys Lys Ser Arg Thr Leu Ser
Glu Asp Asp Phe Arg Arg Phe Phe Arg 1505 1510 1515 1520 Val Trp Asn
Arg Phe Asp Pro Asp Arg Thr Gln Tyr Ile Asp Ser Ser 1525 1530 1535
Lys Leu Ser Asp Phe Ala Ala Ala Leu Asp Pro Pro Leu Phe Met Ala
1540 1545 1550 Lys Pro Asn Lys Gly Gln Leu Val Ala Met Asp Leu Pro
Met Ala Ala 1555 1560 1565 Gly Asp Arg Ile His Cys Leu Asp Ile Leu
Leu Ala Phe Thr Lys Arg 1570 1575 1580 Val Met Gly Lys Asp Glu Arg
Val Glu Lys Ile Leu Ser Glu Ile Glu 1585 1590 1595 1600 Ser Gly Phe
Met Leu Ala Asn Pro Phe Lys Ile Thr Tyr Glu Pro Ile 1605 1610 1615
Thr Thr Thr Leu Lys Arg Lys Gln Glu Ala Val Ser Ala Thr Ile Ile
1620 1625 1630 Gln Arg Ala Tyr Lys Ser Tyr Arg Leu Arg Gln Asn Asp
Lys Asn Val 1635 1640 1645 Ser Asp Thr Pro Ala Ile Asp Asp Arg Arg
Asp Asp Leu Thr Ser Lys 1650 1655 1660 Gly Ala His Ser Gly Lys Ile
Glu Glu Lys Ala Ser Ile Gln Thr Gln 1665 1670 1675 1680 Ile 4 6927
DNA Mus musculus 4 aagctttact ctcacagaga aaagtcttct gagtgatcaa
ttgccaacga tacaacctca 60 ccttagttta ccctgacctg tgaaagatgg
ccttcaacag tggagaataa ggagttctag 120 ctgagatgtt tcattaagcg
acatattcat ggatcagctt ttgatggcag attttcaggc 180 tccttttctc
cactgccaat aattttacaa aacacaattt taaaattgta gtctttatgg 240
gaaacaattc atcctataga tgttgtcaag gacaaaacat tttcactcct gggcagtttt
300 gttgttccct tccctcactg tcatggcgct aaagcggtag ctcatcccca
gattaggggc 360 ccaggtgtaa ttgttcttaa gtctgaaatt gtaggggaga
gttctttgaa ctcatctctt 420 catgagttca aagaacatat gacaacttat
tgatagaatg actttacaca tggccatatt 480 ttacacattt actattttac
aggtataaaa ccgaaaatgt tgacttcccc agagccgaag 540 ggccttgtcc
catttacaac agagtcactt gaacttatag aaaatcacat tgctaaaaaa 600
tgcaatgaag accccgaaga agaagaaggt ttaaaaccaa gtcgtaatct agaagctggc
660 aaaagacttc caattcccta tggaaccctc cctcgaggaa ccgtgtcaga
gcccttggaa 720 gatgtggatc catactacta tgttaagaga aatgtaagta
ttaactgtta tcattgaagc 780 tatattttac ttcgcttata ttcagccact
tgaaatgtaa ttgagataag acttaaagaa 840 aattaataga gaaggcattc
tttcataatc tattctttgt gggggtcaac atgctcaaga 900 tagttaaacc
tgataaaata tctgagtaat atattatggt taatgaccgt agtatatata 960
ctgctattcc ttaatataag tggctattgt gaaaatatgc taattaccat tttctgatta
1020 gcaattttaa aacaatcatg aaatatttag aatatggaca gaaatttcaa
ataccttgat 1080 aacttactag tcaaaacagt acatttattt ttaatcatat
ataaatccac aaattcaaac 1140 ctccctcatt tccaggaaga ctttagagac
ctagaaatta tgtatacaca aacacacaca 1200 cacacataca cacacacaca
cgcacacgca aatgcacacc ctaccatcac aaacacaaaa 1260 taagtacaag
aatgatttct gttagaaaat tcagacatgt ggattgatga agatagatga 1320
gtcttgtttc aaaagcatgg tttgggggct ggagaaatgt ctcagtttct aatagcactg
1380 gctgttcttc tggacgtcat aagattgatt gcagtccctg tacagtaggt
cacagccttt 1440 tgtaactcta gttccagaag atttgacctt cttttggcca
ctatgggcac tgggaatgca 1500 aataattcat atatgcacac agtgaagaca
tctatatact tgaaatgaga taaaatttta 1560 ggtacagctt gcagaatact
tggaatttta ataaagccaa ggtagaacag tttaaggaca 1620 aatggaatgg
caacagccaa gattgattct acaagagggc atagaaaggg ctgtgctatt 1680
actggaaaat cagttatgtt gttgactgtg gcaaacatga gagagtggag gtgtcatcat
1740 ggaattactg tagtggacaa ggtcatttgg ggtgaatgtg gcagatgaat
aaaaccaagc 1800 taataccttt cttaattaaa agaaaagtga tcaatacaga
aaataaaata gaacataaaa 1860 gacagggaga aatataaggt agagaagagg
aggagagaaa gagatgaggg agaagagaag 1920 gggtgagaat gggaagagga
agagaagaga gataggtaga aatgaagaga ggggaggaag 1980 ggacttgtat
attacagtta atttacctag tgtacaaact gatagttctt agtataaatg 2040
gcttttatgt aaatatgatg attactgtct tctaattatc tatttttaaa taatcataaa
2100 atatttacac tataaaagaa aaagagagaa ggaggagaga aagaacaaga
aggaaatagg 2160 gtagagggaa ccctgagatt cagtgtctat gtcaggaaaa
gaaacagtaa aatatgactg 2220 atgaaaaatg ccaatgtctg tagcttgaaa
gagtgaagtt acattgacag aaagtgaaat 2280 aaagtttatt tactagcatc
ttgatattca tgtatcatat tcactgatgt tatatctaat 2340 gaggagatga
gactgaacga aaatatctgc agaaaaatac attcattgca taactgttcc 2400
tataataatg tcatggtgtc atttgaaata ttttaaggac attttagtta aaatgcaagt
2460 tcagtcctca tttgtattgt tctggcactc actttgtggt gtgcttgagt
tgataatggc 2520 cagtaacctt aggattgcct gtcaatattg cagccatctt
aatactgagt aaggtatgca 2580 ggcatgctag acatgggaat actgccattg
aagataaaat caaagctctt aagaaacaaa 2640 acaaatactt tatgacaggc
cccatgtcca gcagtagttg gccaaaaaaa aaaaaaaaaa 2700 ttgtgatttt
gattcttttg tcagggtggc atgtttggag acagggattc cctgagtagc 2760
cctggctgtc ctggaactca ctctgcagtc caggctggcc tcgaactcag agatctgctt
2820 gcttctgtct tctgagttct aggattacgg gtataagttt ttattaaaag
tataaggctt 2880 tgctttttgt tgttgttttt ttttgtttgt ttgtttgttt
tgttttttgg ttggttgttt 2940 ttgttgttgt tggtggtggt ggtggtagtg
gtgtgtgtgt gtgtgtgtgt gtgtgtgtgt 3000 gtgtgtgtgt gtgtgtgtgt
gtgtggaggg agagagagag tgtgctgttt ctgttggaat 3060 tttttgtcat
ttttctttaa cttgttatgt tttggtttct ttgagaaaga atgaaggaac 3120
ctgaagttgg ttggatacgg gtgtggggag gatcttggaa tgagttgaga aaggacaaag
3180 aatataatca aagcttacta tatgaaaaat taaataaaat gtgaaataac
tacaaaaatc 3240 tcaaaacaac attttgagtg atttaggatc ctagcagcta
tgaggcccat gggttgaaat 3300 ttgccagtga cttcatgcac tctaaagcct
gcaaatgtga cttcatgaac tctgaagcct 3360 gccagggtga cctcatgctc
tttgaagcct gactgggtga ctttatgcac tcagtgctgc 3420 tctcagtaac
atcacactgt tcaagtatct gggttgtatt tggcttactc tcttacacat 3480
agcacagaga caaataatca taaaattaag actatgtatg aaatcaggag aaaacctgaa
3540 agtacgcatc ccttcacaat gacacacaca tatattgaac tccacatgga
gtctgcaatt 3600 gttttggaag ctactatgga aagtagaatt tacacaacca
ggtatattat ttgtttctac 3660 ctgttttatt taagtggaga tgggagaata
ggtacaatag ttaaacaaag cctcatagca 3720 gttatatatt gaactacact
tatctgagaa ttgagaccca gagtagattc cagttagagc 3780 agacatgcat
ggagaagtgt tggcagttgt atattcttat aatttctttt tcatatgcgt 3840
ctgtcaacat aggaagcaat aagtcatacc tcctatatca ttatcagaat atatggtaga
3900 ctgtatagtc tattctattg catataagat taatttttaa gccaggcctt
ctggcagggc 3960 tataattctc aaacaacaaa gtattgcaga ttcaagtcct
ctgtggtcta aactgtgagt 4020 tcaaggtcag ccttaacaat ttaatgaaat
ctattttcaa gagaaaaaga atataaagat 4080 cctcaggaga aataatggaa
gagagtttgc ccagcacaca tgaggcccct gtcacagagg 4140 aagaaaatat
tacatatttt ttatttataa aaatatagtt atcttattat ataacatgct 4200
atgttatgtt atgttttatg ttataacaca tgacatttaa tctcatagtt ttcagaatta
4260 actggatttt cagtgttagc tggatcaaac tcagggcctg ctgaagggtg
aacaaacact 4320 gttcttcaag ttacattacc agacagtaca tgttaatgca
cccctacatt aatactttct 4380 ctgaagggac atatatagta aacacacaca
cacacacaca cacacatata tatatatata 4440 catatacaca cacacatata
tatatacact ttcaattacc atatataata tataccatat 4500 acattatagt
aatgttcatt tatatgaaca aatgtaaaaa tgagcacaca tatgtatgaa 4560
tgtacataag cccacatgta catatgtata aataagccca tccacctacc tatatattga
4620 acaatgtctg ttttagaata tttatgtttc ttactatatt tattaagact
tagtacttta 4680 gtatccacaa tccttgtgtt tatattacat aaattactat
ttttagatag gttcatatca 4740 ataatattaa ataagttagg ttttgtaaaa
acattaattt ttaggattta ccttgtaatt 4800 gttttatttt tttattcgat
attttcttta tttacatttc aaatgctttc ccgaaagtcc 4860 cctataccct
cccacctccc tgctccccta ctcacccact cccatttctt ggccctggtg 4920
ttcccctgta ttggggcata taaagtttgc aagaccaagg ggtctctatt cccaatgatg
4980 gccgactagg ccatcttctg ctacatattc agctagagac acgagctctg
gggatactgg 5040 ttaataattg ttttattttt aatatatttt atttaaaata
gaattacata aattatcctc 5100 ttattttctc ccctacagtg tctccctcat
aaataatata aacaattgat gtgagatttg 5160 accattgctt ttataacact
tcattgactt tttttctgat ataaaattaa aatttttaca 5220 ttcattaagt
tatgagataa aggccctctg atgctttgaa tgcaaatcca cacaccatct 5280
gaagagtttc tttttcatta gttcaaggtg tgattgcacc ataatgactt tcttaagtac
5340 aaaccagcaa aaaataaata aattaattaa ttattaaaat aaaataagtg
gtgagctatc 5400 aggcaagtcc aaatataagt gaaaactact ccctttgctt
taaaaacaaa tgtcaaagcc 5460 aatgaaaata tgaaataatt tcaaactggt
gagcattggt aatatgttgc ttcagttctc 5520 cattctgttt gttaatgtct
ttcctgtggt tccttacaga ctttcatggt cttaaacaga 5580 agcagagtca
tcttcaggtt caatgcggtt tccatcttct gcacattgtc tcctctaaac 5640
tccctcagaa gagcagctat caaggctttg gtgcatccat atcctttcaa agtgtgatgg
5700 gttgtgtcat cggcatacta aaaataagtc ctgatgttct gtcattcaac
ccctgttgta 5760 gtaatattta acaaatatca attcttattc ttcaaataga
atgacatgta ttttcaatat 5820 ttacaaaaga atctcgcccc ttatatctac
agatgcaatt tactggtctt ttgtaatgtg 5880 atttcttctc cattattcct
tgaccctggc ttaccctttt tcgcctgctg attttaatca 5940 gcgttctcac
tgacagcata cttatgtgca tgagtaatct accagaatgg atattggcaa 6000
tagagtaagt tacttagttt tgctatatat aataaagtct gtaattatat tttggtttta
6060 acattttaat atttattgta ttccattaaa ttacaaaaac atgttatgaa
atgaaacatg 6120 atactattta aatttttaaa tgtttaaaaa agttataaag
acaagaggtt tgtttcactc 6180 acagctttga aggttcaaga gcacctatgc
tgttcagctt cagggacaat taggtcctct 6240 cacctaatta acctgtggcc
tgtggaaaca ggagaagctc tttcagaagc agccattcat 6300 gtcttgatgc
tgtaagccca tgactggtat gaagcctgcc acaacttttc tcttactctt 6360
cttgtgggtc ttgtgcaaac aagcaggcat gcgctccagt gccacaagga ccttcaagtg
6420 caccccacgt ctagtgctcc gtaaactctt gcctcaccat gatcgggatc
aagttctaaa 6480 tatgtagaat attgtagaca tctgaaaaca aacctcatct
tcatatttct tttctgtata 6540 tactcgtatg tttgtggggc atagcaatat
gaacaccatg actaaatttt ctaaataaaa 6600 caaacatgta tatgcacata
cacatatata tagatgtata ttcatcaatt tggggtttta 6660 ttttgccctt
tcattcttct tacttaattc ctgttggtgt tattttattt gattcatgtt 6720
ctttatacca cttgcctttg actcctgttc cagactcttg aatcctggaa ttacatcttc
6780 ttatcacgac tttacatatc tacagttcta tatagactga aggtttaatt
atattaatta 6840 attatgttca ttggaatatt taggtccttt gctaaatgta
tataccatgt ttcacctcat 6900 gcttgttttc ttccttattt aaagctt 6927 5 20
DNA Artificial Sequence Description of Artificial SequencePrimer1 5
atgttgactt ccccagagcc 20 6 20 DNA Artificial Sequence Description
of Artificial SequencePrimer2 6 aaccaggcaa agcgccattc 20 7 21 DNA
Artificial Sequence Description of Artificial SequencePrimer3 7
catcttccaa gggctctgac a 21 8 16 PRT Rattus norvegicus 8 Ser Val Ser
Glu Thr Val Pro Ile Ala Ser Gly Glu Ser Asp Ile Lys 1 5 10 15
* * * * *